BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. Journal of Hepatology 2008;48:148-62. [DOI: 10.1016/j.jhep.2007.07.033] [Cited by in Crossref: 303] [Cited by in F6Publishing: 293] [Article Influence: 21.6] [Reference Citation Analysis]
Number Citing Articles
1 Brook G, Soriano V, Bergin C. European guideline for the management of hepatitis B and C virus infections, 2010. Int J STD AIDS 2010;21:669-78. [DOI: 10.1258/ijsa.2010.010234] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
2 Kang I, Wang L, Hsu S, Lee C, Lee Y, Wu Y, Yueh A, Wang J, Hsu T, Chao Y, Chern J. Design and efficient synthesis of novel arylthiourea derivatives as potent hepatitis C virus inhibitors. Bioorganic & Medicinal Chemistry Letters 2009;19:6063-8. [DOI: 10.1016/j.bmcl.2009.09.037] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
3 Uhanova J, Tate RB, Tataryn DJ, Minuk GY. A population-based study of the epidemiology of hepatitis C in a North American population. J Hepatol. 2012;57:736-742. [PMID: 22668641 DOI: 10.1016/j.jhep.2012.05.018] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
4 Vučetić D, Jovičić M, Maslovarić I, Bogdanović S, Antić A, Stanojković Z, Filimonović G, Ilić V. Transfusion-transmissible infections among Serbian blood donors: declining trends over the period 2005-2017. Blood Transfus 2019;17:336-46. [PMID: 30865580 DOI: 10.2450/2019.0185-18] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Tozun N, Ozdogan O, Cakaloglu Y, Idilman R, Karasu Z, Akarca U, Kaymakoglu S, Ergonul O. Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect 2015;21:1020-6. [PMID: 26163105 DOI: 10.1016/j.cmi.2015.06.028] [Cited by in Crossref: 53] [Cited by in F6Publishing: 39] [Article Influence: 7.6] [Reference Citation Analysis]
6 Fuster D, Muga R, Simon O, Bertholet N. Current Opioid Access, Use, and Problems in Central and Western European Jurisdictions. Curr Addict Rep 2018;5:478-84. [DOI: 10.1007/s40429-018-0226-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Winston A, Wurcel AG, Gordon C, Goyal N. Viral hepatitis in patients on hemodialysis. Semin Dial 2020;33:254-62. [PMID: 32394502 DOI: 10.1111/sdi.12882] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Trias-llimós S, Bijlsma MJ, Janssen F. The role of birth cohorts in long-term trends in liver cirrhosis mortality across eight European countries: Liver cirrhosis deaths by birth cohort. Addiction 2017;112:250-8. [DOI: 10.1111/add.13614] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
9 Khattab MA, Ferenci P, Hadziyannis SJ, Colombo M, Manns MP, Almasio PL, Esteban R, Abdo AA, Harrison SA, Ibrahim N, Cacoub P, Eslam M, Lee SS. Management of hepatitis C virus genotype 4: Recommendations of An International Expert Panel. Journal of Hepatology 2011;54:1250-62. [DOI: 10.1016/j.jhep.2010.11.016] [Cited by in Crossref: 86] [Cited by in F6Publishing: 84] [Article Influence: 7.8] [Reference Citation Analysis]
10 Owiti JA, Greenhalgh T, Sweeney L, Foster GR, Bhui KS. Illness perceptions and explanatory models of viral hepatitis B & C among immigrants and refugees: a narrative systematic review. BMC Public Health 2015;15:151. [PMID: 25886390 DOI: 10.1186/s12889-015-1476-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
11 Tavoschi L, Mason L, Petriti U, Bunge E, Veldhuijzen I, Duffell E. Hepatitis B and C among healthcare workers and patient groups at increased risk of iatrogenic transmission in the European Union/European Economic Area. J Hosp Infect 2019;102:359-68. [PMID: 30885816 DOI: 10.1016/j.jhin.2019.03.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
12 Saghir M, Shaheen N, Shah MH. Comparative Evaluation of Trace Metals in the Blood of Hepatitis C Patients and Healthy Donors. Biol Trace Elem Res 2011;143:751-63. [DOI: 10.1007/s12011-010-8930-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
13 Palmateer NE, Hutchinson SJ, Innes H, Schnier C, Wu O, Goldberg DJ, Hickman M. Review and meta-analysis of the association between self-reported sharing of needles/syringes and hepatitis C virus prevalence and incidence among people who inject drugs in Europe. International Journal of Drug Policy 2013;24:85-100. [DOI: 10.1016/j.drugpo.2012.08.006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
14 Min JA, Yoon Y, Lee HJ, Choi J, Kwon M, Kim K, Lee CU, Kim DJ, Yun H. Prevalence and associated clinical characteristics of hepatitis B, C, and HIV infections among injecting drug users in Korea. J Med Virol 2013;85:575-82. [PMID: 23364858 DOI: 10.1002/jmv.23523] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
15 Pittman ME. Hepatocellular carcinoma: a practical review for the surgical pathologist. Diagnostic Histopathology 2018;24:500-7. [DOI: 10.1016/j.mpdhp.2018.09.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Aguilera A, Navarro D, Rodríguez-Frias F, Viciana I, Martínez-Sapiña AM, Rodríguez MJ, Martró E, Lozano MC, Coletta E, Cardeñoso L, Suárez A, Trigo M, Rodríguez-Granjer J, Montiel N, de la Iglesia A, Alados JC, Vegas C, Bernal S, Fernández-Cuenca F, Pena MJ, Reina G, García-Bujalance S, Echevarria MJ, Benítez L, Pérez-Castro S, Ocete D, García-Arata I, Guerrero C, Rodríguez-Iglesias M, Casas P, García F. Prevalence and distribution of hepatitis C virus genotypes in Spain during the 2000-2015 period (the GEHEP 005 study). J Viral Hepat 2017;24:725-32. [PMID: 28248445 DOI: 10.1111/jvh.12700] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
17 Shouval D. Focus. Journal of Hepatology 2014;60:239-40. [DOI: 10.1016/j.jhep.2013.11.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
18 Matas M, Picornell A, Cifuentes C, Payeras A, Bassa A, Homar F, López-Labrador FX, Moya A, Ramon MM, Castro JA. Relating the liver damage with hepatitis C virus polymorphism in core region and human variables in HIV-1-coinfected patients. Infect Genet Evol 2010;10:1252-61. [PMID: 20732459 DOI: 10.1016/j.meegid.2010.08.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
19 Andriulli A, Stroffolini T, Mariano A, Valvano MR, Grattagliano I, Ippolito AM, Grossi A, Brancaccio G, Coco C, Russello M, Smedile A, Petrini E, Martini S, Gaeta GB, Rizzetto M. Declining prevalence and increasing awareness of HCV infection in Italy: A population-based survey in five metropolitan areas. Eur J Intern Med. 2018;53:79-84. [PMID: 29475770 DOI: 10.1016/j.ejim.2018.02.015] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 10.3] [Reference Citation Analysis]
20 Palladino C, Ezeonwumelu IJ, Marcelino R, Briz V, Moranguinho I, Serejo F, Velosa JF, Marinho RT, Borrego P, Taveira N. Epidemic history of hepatitis C virus genotypes and subtypes in Portugal. Sci Rep. 2018;8:12266. [PMID: 30116054 DOI: 10.1038/s41598-018-30528-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
21 Li Y, Wang R, Du X, Zhang M, Xie M. Genome-wide analysis for identification of adaptive diversification between hepatitis C virus subtypes 1a and 1b. Can J Microbiol 2016;62:608-16. [PMID: 27277863 DOI: 10.1139/cjm-2016-0156] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Henquell C, Guglielmini J, Verbeeck J, Mahul A, Thibault V, Lebray P, Laperche S, Trimoulet P, Foucher J, Le Guillou-guillemette H, Fouchard-hubert I, Legrand-abravanel F, Métivier S, Gaudy C, D’alteroche L, Rosenberg AR, Podevin P, Plantier J, Riachi G, Saoudin H, Coppere H, André E, Gournay J, Feray C, Vallet S, Nousbaum J, Baazia Y, Roulot D, Alain S, Loustaud-ratti V, Schvoerer E, Habersetzer F, Pérez-serra RJ, Gourari S, Mirand A, Odent-malaure H, Garraud O, Izopet J, Bommelaer G, Peigue-lafeuille H, van Ranst M, Abergel A, Bailly J. Evolutionary history of hepatitis C virus genotype 5a in France, a multicenter ANRS study. Infection, Genetics and Evolution 2011;11:496-503. [DOI: 10.1016/j.meegid.2010.12.015] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
23 Taghavi SA, Eshraghian A. Successful interferon desensitization in a patient with chronic hepatitis C infection. World J Gastroenterol 2009; 15(33): 4196-4198 [PMID: 19725157 DOI: 10.3748/wjg.15.4196] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
24 Faustini A, Colais P, Fabrizi E, Bargagli AM, Davoli M, Di Lallo D, Di Napoli A, Pezzotti P, Sorge C, Grillo R, Maresca C, Recchia O, Perucci CA; HCV laboratory surveillance Lazio-Region Group. Hepatic and extra-hepatic sequelae, and prevalence of viral hepatitis C infection estimated from routine data in at-risk groups. BMC Infect Dis 2010;10:97. [PMID: 20403169 DOI: 10.1186/1471-2334-10-97] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
25 Duffell EF, van de Laar MJ, Amato-Gauci AJ. Enhanced surveillance of hepatitis C in the EU, 2006 - 2012. J Viral Hepat 2015;22:590-5. [PMID: 25420699 DOI: 10.1111/jvh.12367] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
26 Li Cavoli G, Ferrantelli A, Bono L, Tortorici C, Giammarresi C, Zagarrigo C, Schillaci O, Tralongo A, Soresi M, Rotolo U. Incidence of hepatitis C virus infection in patients with chronic kidney disease on conservative therapy. Int J Infect Dis. 2011;15:e514-e516. [PMID: 21680217 DOI: 10.1016/j.ijid.2011.04.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
27 da Rocha MC, Marinho RT, Rodrigues T. Mortality Associated with Hepatobiliary Disease in Portugal between 2006 and 2012. GE Port J Gastroenterol 2018;25:123-31. [PMID: 29761148 DOI: 10.1159/000484868] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
28 Leite RB. Consensus for the integrated management of hepatitis C in Portugal. BMC Infect Dis 2014;14 Suppl 6:S9. [PMID: 25252812 DOI: 10.1186/1471-2334-14-S6-S9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
29 Oliveira Mde L, Bastos FI, Telles PR, Hacker Mde A, Oliveira SA, Miguel JC, Yoshida CF. Epidemiological and genetic analyses of Hepatitis C virus transmission among young/short- and long-term injecting drug users from Rio de Janeiro, Brazil. J Clin Virol 2009;44:200-6. [PMID: 19195927 DOI: 10.1016/j.jcv.2008.12.008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
30 Raggam RB, Rossmann AM, Salzer HJ, Stauber RE, Kessler HH. Health care worker-to-patient transmission of hepatitis C virus in the health care setting: Many questions and few answers. J Clin Virol. 2009;45:272-275. [PMID: 19477680 DOI: 10.1016/j.jcv.2009.04.015] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
31 Di Lello FA, Culasso AC, Campos RH. Inter and intrapatient evolution of hepatitis C virus. Annals of Hepatology 2015;14:442-9. [DOI: 10.1016/s1665-2681(19)31164-0] [Cited by in Crossref: 8] [Article Influence: 1.1] [Reference Citation Analysis]
32 Sereno S, Perinelli P, Laghi V. Changes in the prevalence of hepatitis C virus genotype among Italian injection drug users-relation to period of injection started. J Clin Virol. 2009;45:354-357. [PMID: 19497783 DOI: 10.1016/j.jcv.2009.04.022] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
33 van der Helm JJ, Prins M, del Amo J, Bucher HC, Chêne G, Dorrucci M, Gill J, Hamouda O, Sannes M, Porter K, Geskus RB; CASCADE Collaboration. The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007. AIDS 2011;25:1083-91. [PMID: 21537114 DOI: 10.1097/QAD.0b013e3283471cce] [Cited by in Crossref: 103] [Cited by in F6Publishing: 46] [Article Influence: 9.4] [Reference Citation Analysis]
34 Frazer K, Glacken M, Coughlan B, Staines A, Daly L. Hepatitis C virus infection in primary care: survey of registered nurses' knowledge and access to information. J Adv Nurs 2011;67:327-39. [PMID: 21044133 DOI: 10.1111/j.1365-2648.2010.05489.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
35 Méndez-sánchez N, Gadano A, Alves de Mattos A, Soza A, Claudio AM, Galoppo M, Kershenobich D, Strauss E, Fassio E, Castañeda G, Valladares G, Coelho HSM, Daruich J, Garassini M, Dávalos M, Uribe M, Rodriguez-torres M, Zapata R, Arrese M, Sánchez-ávila F, Dehesa M, Padilla FB, Lerias de Almeida PR, Pessoa M, Torres-ibarra R, Hevia F, Contreras M, Cheinquer H. Latin American Association for the Study of the Liver Practice Guidelines. Annals of Hepatology 2010;9:S8-S26. [DOI: 10.1016/s1665-2681(19)31718-1] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
36 Dultz G, Zeuzem S. Hepatitis C Virus: A European Perspective. Gastroenterol Clin North Am. 2015;44:807-824. [PMID: 26600221 DOI: 10.1016/j.gtc.2015.07.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
37 Alonso López S, Agudo Fernández S, García Del Val A, Martínez Abad M, López Hermosa Seseña P, Izquierdo MJ, Núñez I, Berbel León S, Visedo Campillo L, Guisado Pérez C, Sánchez Lozano S, Mariño Pfeiffer I, García Bermúdez L, Sánchez Jiménez FJ, López Vega E, Zambrano Álvarez J, Castro Pastor ML, Montes Ramírez G, Murillo C, Villafranca Ortega N, Ayuso Hernández I, Espejo M, Lasala López P, Rodríguez Caravaca G, Carrascosa Aguilar B, Gutiérrez García ML, Fernández Rodríguez C. Hepatitis C seroprevalence in an at-risk population in the southwest Madrid region of Spain. Gastroenterol Hepatol 2016;39:656-62. [PMID: 27417563 DOI: 10.1016/j.gastrohep.2016.05.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
38 V Picon R, Fendt L, Amaral K, D Picon P. Prediction of Sustained Virological Response to Peginterferon-based Therapy for Chronic Hepatitis C: Regression Analysis of a Cohort from Rio Grande do Sul, Brazil. Euroasian J Hepatogastroenterol 2017;7:27-33. [PMID: 29201768 DOI: 10.5005/jp-journals-10018-1207] [Reference Citation Analysis]
39 Colomba GME, Urone N, Marco VD, Ferraro D. Phylodynamic Analysis and Implication of HCV Genotype 4 Variability on Antiviral Drug Response and T-Cell Recognition. Viruses 2020;12:E1363. [PMID: 33260596 DOI: 10.3390/v12121363] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Falla AM, Hofstraat SHI, Duffell E, Hahné SJM, Tavoschi L, Veldhuijzen IK. Hepatitis B/C in the countries of the EU/EEA: a systematic review of the prevalence among at-risk groups. BMC Infect Dis 2018;18:79. [PMID: 29433454 DOI: 10.1186/s12879-018-2988-x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 11.8] [Reference Citation Analysis]
41 Tronina O, Ślubowska K, Mikołajczyk-Korniak N, Komuda-Leszek E, Wieczorek-Godlewska R, Łągiewska B, Pacholczyk M, Lisik W, Kosieradzki M, Durlik M. Fibrosing Cholestatic Hepatitis C After Liver Transplantation: Therapeutic Options Before and After Introduction of Direct-Acting Antivirals: Our Experience and Literature Review. Transplant Proc 2017;49:1409-18. [PMID: 28736015 DOI: 10.1016/j.transproceed.2017.01.077] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
42 Howell J, Pedrana A, Cowie BC, Doyle J, Getahun A, Ward J, Gane E, Cunningham C, Wallace J, Lee A, Malani J, Thompson A, Hellard ME. Aiming for the elimination of viral hepatitis in Australia, New Zealand, and the Pacific Islands and Territories: Where are we now and barriers to meeting World Health Organization targets by 2030. J Gastroenterol Hepatol. 2019;34:40-48. [PMID: 30151932 DOI: 10.1111/jgh.14457] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
43 Kahraman A, Fingas CD, Syn WK, Gerken G, Canbay A. Role of stress-induced NKG2D ligands in liver diseases. Liver Int. 2012;32:370-382. [PMID: 22097967 DOI: 10.1111/j.1478-3231.2011.02608.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
44 Edeghere O, Verlander NQ, Aboulhab J, Costella A, Harris HE, Balogun MA, Ramsay ME. Retrospective cohort study of liver transplantation in the United Kingdom between 1994 and 2010: the impact of hepatitis C infection. Public Health 2015;129:509-16. [PMID: 25726124 DOI: 10.1016/j.puhe.2015.01.024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
45 Pizzillo P, Almasio PL, Ferraro D, Craxì A, Di Stefano R. HCV genotypes in Sicily: Is there any evidence of a shift? J Med Virol 2009;81:1040-6. [DOI: 10.1002/jmv.21498] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
46 Sharma S, Carballo M, Feld JJ, Janssen HL. Immigration and viral hepatitis. J Hepatol. 2015;63:515-522. [PMID: 25962882 DOI: 10.1016/j.jhep.2015.04.026] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 9.1] [Reference Citation Analysis]
47 Spada E, Mele A, Mariano A, Zuccaro O, Tosti ME. Risk factors for and incidence of acute hepatitis C after the achievement of blood supply safety in Italy: results from the national surveillance system. J Med Virol. 2013;85:433-440. [PMID: 23280786 DOI: 10.1002/jmv.23485] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
48 Demetriou VL, van de Vijver DA, Hezka J, Kostrikis LG, Kostrikis LG. Hepatitis C infection among intravenous drug users attending therapy programs in Cyprus. J Med Virol. 2010;82:263-270. [PMID: 20029809 DOI: 10.1002/jmv.21690] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
49 González-Candelas F, Guiral S, Carbó R, Valero A, Vanaclocha H, González F, Bracho MA. Patient-to-patient transmission of hepatitis C virus (HCV) during colonoscopy diagnosis. Virol J 2010;7:217. [PMID: 20825635 DOI: 10.1186/1743-422X-7-217] [Cited by in Crossref: 20] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
50 Van Herck K, Vorsters A, Van Damme P. Prevention of viral hepatitis (B and C) reassessed. Best Practice & Research Clinical Gastroenterology 2008;22:1009-29. [DOI: 10.1016/j.bpg.2008.11.008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
51 Thöns C, Senff T, Hydes TJ, Manser AR, Heinemann FM, Heinold A, Heilmann M, Kim AY, Uhrberg M, Scherbaum N, Lauer GM, Khakoo SI, Timm J. HLA-Bw4 80(T) and multiple HLA-Bw4 copies combined with KIR3DL1 associate with spontaneous clearance of HCV infection in people who inject drugs. J Hepatol 2017;67:462-70. [PMID: 28412292 DOI: 10.1016/j.jhep.2017.03.040] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
52 Salloum S, Kluge SF, Kim AY, Roggendorf M, Timm J. The resistance mutation R155K in the NS3/4A protease of hepatitis C virus also leads the virus to escape from HLA-A*68-restricted CD8 T cells. Antiviral Res 2010;87:272-5. [PMID: 20488208 DOI: 10.1016/j.antiviral.2010.05.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
53 Vriend HJ, Van Veen MG, Prins M, Urbanus AT, Boot HJ, Op De Coul EL. Hepatitis C virus prevalence in The Netherlands: migrants account for most infections. Epidemiol Infect 2013;141:1310-7. [PMID: 22963908 DOI: 10.1017/S0950268812001884] [Cited by in Crossref: 33] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
54 Ross RS, Stambouli O, Grüner N, Marcus U, Cai W, Zhang W, Zimmermann R, Roggendorf M. Detection of infections with hepatitis B virus, hepatitis C virus, and human immunodeficiency virus by analyses of dried blood spots--performance characteristics of the ARCHITECT system and two commercial assays for nucleic acid amplification. Virol J. 2013;10:72. [PMID: 23497102 DOI: 10.1016/j.antiviral.2011.12.011] [Cited by in Crossref: 92] [Cited by in F6Publishing: 80] [Article Influence: 10.2] [Reference Citation Analysis]
55 Abdel-wahhab MA, Gamil K, El-kady AA, El-nekeety AA, Naguib KM. Therapeutic Effects of Korean Red Ginseng Extract in Egyptian Patients with Chronic Liver Diseases. Journal of Ginseng Research 2011;35:69-79. [DOI: 10.5142/jgr.2011.35.1.069] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
56 Marco A, Esteban J, Solé C, da Silva A, Ortiz J, Roget M, Sarriera C, Teixidó N, Guerrero R, Caylà J. Hepatitis C virus reinfection among prisoners with sustained virological response after treatment for chronic hepatitis C. Journal of Hepatology 2013;59:45-51. [DOI: 10.1016/j.jhep.2013.03.008] [Cited by in Crossref: 44] [Cited by in F6Publishing: 48] [Article Influence: 4.9] [Reference Citation Analysis]
57 Steinebrunner N, Sprinzl MF, Zimmermann T, Wörns MA, Zimmerer T, Galle PR, Stremmel W, Eisenbach C, Stein K, Antoni C, Schattenberg JM, Pathil A. Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center "real-life" cohort. BMC Gastroenterol 2015;15:97. [PMID: 26239732 DOI: 10.1186/s12876-015-0328-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
58 Sultana C, Vagu C, Temereanca A, Grancea C, Slobozeanu J, Ruta S. Hepatitis C Virus Genotypes in Injecting Drug Users from Romania. Cent Eur J Med. 2011;6:672-678. [PMID: 23585824 DOI: 10.2478/s11536-011-0073-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
59 Michel L, Trouiller P, Chollet A, Molinier M, Duchesne L, Jauffret-Roustide M; ANRS-Coquelicot Study Group. Self-reported injection practices among people who use drugs in French prisons: Public health implications (ANRS-Coquelicot survey 2011-2013). Drug Alcohol Rev 2018;37 Suppl 1:S268-76. [PMID: 29105203 DOI: 10.1111/dar.12620] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
60 Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013;10:553-562. [PMID: 23817321 DOI: 10.1038/nrgastro.2013.107] [Cited by in Crossref: 625] [Cited by in F6Publishing: 583] [Article Influence: 69.4] [Reference Citation Analysis]
61 Yan Z, Fan K, Wang Y, Fan Y, Tan Z, Deng G. Changing Pattern of Clinical Epidemiology on Hepatitis C Virus Infection in Southwest China. Hepat Mon 2012;12:196-204. [DOI: 10.5812/hepatmon.5123] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
62 Le Ngoc C, Tran Thi Thanh T, Tran Thi Lan P, Nguyen Mai T, Nguyen Hoa T, Nghiem My N, Le Van T, Le Manh H, Le Thanh P, Nguyen Van Vinh C, Thwaites G, Cooke G, Heilek GM, Shikuma C, Le T, Baker S, Rahman M; VIZIONS consortium. Differential prevalence and geographic distribution of hepatitis C virus genotypes in acute and chronic hepatitis C patients in Vietnam. PLoS One 2019;14:e0212734. [PMID: 30865664 DOI: 10.1371/journal.pone.0212734] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
63 Delotte J, Barjoan EM, Berrébi A, Laffont C, Benos P, Pradier C, Bongain A. Obstetric management does not influence vertical transmission of HCV infection: results of the ALHICE group study. J Matern Fetal Neonatal Med. 2014;27:664-670. [PMID: 23971940 DOI: 10.3109/14767058.2013.829813] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
64 Balaeva T, Grjibovski AM, Samodova O, Sannikov A, Klouman E. Seroprevalence of markers of hepatitis C virus exposure and associated factors in adults aged 18-39 years in the Arctic Russian city of Arkhangelsk: a cross-sectional study. Int J Circumpolar Health 2019;78:1648970. [PMID: 31370746 DOI: 10.1080/22423982.2019.1648970] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
65 Madsen LW, Fabricius T, Hjerrild S, Hansen TM, Mössner BK, Birkemose I, Skamling M, Christensen PB. Depressive symptoms are frequent among drug users, but not associated with hepatitis C infection. Scand J Infect Dis 2014;46:566-72. [PMID: 24934987 DOI: 10.3109/00365548.2014.918274] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
66 Pluta M, Pokorska-Śpiewak M, Aniszewska M, Kowalik-Mikołajewska B, Marczyńska M. Progress and Barriers Towards Elimination of Chronic Hepatitis C in Children. Klin Padiatr 2020. [PMID: 33339066 DOI: 10.1055/a-1304-3542] [Reference Citation Analysis]
67 Tramuto F, Mazzucco W, Maida CM, Affronti A, Affronti M, Montalto G, Vitale F. Serological pattern of Hepatitis B, C, and HIV infections among immigrants in Sicily: epidemiological aspects and implication on public health. J Community Health 2012;37:547-53. [PMID: 21922163 DOI: 10.1007/s10900-011-9477-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
68 Martini A, Fattovich G, Guido M, Bugianesi E, Biasiolo A, Ieluzzi D, Gallotta A, Fassina G, Merkel C, Gatta A, Negro F, Pontisso P. HCV genotype 3 and squamous cell carcinoma antigen (SCCA)-IgM are independently associated with histological features of NASH in HCV-infected patients. J Viral Hepat 2015;22:800-8. [DOI: 10.1111/jvh.12394] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
69 Shin SK, Park SY, Jung YK, Kim EJ, Lee HN, Lee JJ, Kwon OS, Choi DJ, Kim YS, Kim JH. [Prevalence, risk factors and clinical characteristics in patients with genotype 6 chronic hepatitis C: a single institute experience]. Korean J Gastroenterol 2015;65:105-11. [PMID: 25716713 DOI: 10.4166/kjg.2015.65.2.105] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
70 Shoeb D, Rowe IA, Freshwater D, Mutimer D, Brown A, Moreea S, Sood R, Marley R, Sabin CA, Foster GR. Response to antiviral therapy in patients with genotype 3 chronic hepatitis C: fibrosis but not race encourages relapse. Eur J Gastroenterol Hepatol. 2011;23:747-753. [PMID: 21691208 DOI: 10.1097/meg.0b013e3283488aba] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
71 Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546-1555. [PMID: 26231459 DOI: 10.1016/s0140-6736(15)61412-x] [Cited by in Crossref: 1422] [Cited by in F6Publishing: 705] [Article Influence: 203.1] [Reference Citation Analysis]
72 Shepherd SJ, Abdelrahman T, MacLean AR, Thomson EC, Aitken C, Gunson RN. Prevalence of HCV NS3 pre-treatment resistance associated amino acid variants within a Scottish cohort. J Clin Virol 2015;65:50-3. [PMID: 25766988 DOI: 10.1016/j.jcv.2015.02.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
73 Cuypers L, Pérez AB, Chueca N, Aldamiz-Echevarría T, Alados JC, Martínez-Sapiña AM, Merino D, Pineda JA, Téllez F, Espinosa N, Salméron J, Rivero-Juarez A, Vivancos MJ, Hontañón V, Vandamme AM, García F. Relapse or reinfection after failing hepatitis C direct acting antiviral treatment: Unravelled by phylogenetic analysis. PLoS One 2018;13:e0201268. [PMID: 30044871 DOI: 10.1371/journal.pone.0201268] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
74 Koletzki D, Dumont S, Vermeiren H, Peixe P, Nina J, Camacho RJ, Stuyver LJ. Full genome sequence of three isolates of hepatitis C virus subtype 4b from Portugal. Arch Virol 2009;154:127-32. [PMID: 19050819 DOI: 10.1007/s00705-008-0270-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
75 Maticic M, Videcnik Zorman J, Gregorcic S, Schatz E, Lazarus JV. Are there national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs? A survey of 33 European countries. BMC Infect Dis 2014;14 Suppl 6:S14. [PMID: 25252635 DOI: 10.1186/1471-2334-14-S6-S14] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
76 Kim DY, Kim IH, Jeong SH, Cho YK, Lee JH, Jin YJ, Lee D, Suh DJ, Han KH, Park NH, Kang HY, Jung YK, Kim YS, Kim KA, Lee YJ, Lee BS, Yim HJ, Lee HJ, Baik SK, Tak WY, Lee SJ, Chung WJ, Choi SK, Cho EY, Heo J, Kim DJ, Song BC, Kim MW, Lee J, Chae HB, Choi DH, Choi HY, Ki M. A nationwide seroepidemiology of hepatitis C virus infection in South Korea. Liver Int 2013;33:586-94. [PMID: 23356674 DOI: 10.1111/liv.12108] [Cited by in Crossref: 69] [Cited by in F6Publishing: 61] [Article Influence: 7.7] [Reference Citation Analysis]
77 Rodriguez-frias F, Nieto-aponte L, Gregori J, Garcia-cehic D, Casillas R, Tabernero D, Homs M, Blasi M, Vila M, Chen Q, Vargas V, Castells L, Viladomiu L, Genesca J, Minguez B, Augustin S, Riveiro-barciela M, Carbonell J, Perales C, Soria M, Asensio M, Llorens M, Ordeig L, Godoy C, Buti M, Esteban R, Pumarola T, Esteban J, Quer J. High HCV subtype heterogeneity in a chronically infected general population revealed by high-resolution hepatitis C virus subtyping. Clinical Microbiology and Infection 2017;23:775.e1-6. [DOI: 10.1016/j.cmi.2017.02.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
78 Saleh O, Baiomy AA, El-desouky A, Zaghloul H, El-Arman M, Dahab GM, Abdel-Rahman MS. Hepatitis C virus genotype distribution in Egyptian diabetic patients: a preliminary study. Arab J Gastroenterol 2013;14:14-9. [PMID: 23622804 DOI: 10.1016/j.ajg.2013.01.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
79 Werner CR, Franz C, Egetemeyr DP, Janke-Maier P, Malek NP, Lauer UM, Berg CP. Efficacy and safety of telaprevir (TVR) triple therapy in a ‘real-life’ cohort of 102 patients with HCV genotype 1: interim analysis after 24 weeks of treatment. J Viral Hepat. 2014;21:333-340. [PMID: 24716636 DOI: 10.1111/jvh.12145] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
80 Zanini B, Covolo L, Donato F, Lanzini A. Effectiveness and tolerability of combination treatment of chronic hepatitis C in illicit drug users: meta-analysis of prospective studies. Clin Ther. 2010;32:2139-2159. [PMID: 21316533 DOI: 10.1016/s0149-2918(11)00021-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
81 Petruzziello A, Marigliano S, Loquercio G, Cacciapuoti C. Hepatitis C virus (HCV) genotypes distribution: an epidemiological up-date in Europe. Infect Agent Cancer. 2016;11:53. [PMID: 27752280 DOI: 10.1186/s13027-016-0099-0] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 6.8] [Reference Citation Analysis]
82 Dencs A, Hettmann A, Martyin T, Jekkel C, Bányai T, Takács M. Phylogenetic investigation of nosocomial transmission of hepatitis C virus in an oncology ward. J Med Virol 2011;83:428-36. [PMID: 21264863 DOI: 10.1002/jmv.21983] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
83 Silva T, Cortes Martins H, Coutinho R, Leitão E, Silva R, Pádua E. Molecular characterization of hepatitis C virus for determination of subtypes and detection of resistance mutations to protease inhibitors in a group of intravenous drug users co-infected with HIV: NS3 HCV Subtyping and Detection of Resistance Mutations. J Med Virol 2015;87:1549-57. [DOI: 10.1002/jmv.24213] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
84 Polilli E, Tontodonati M, Flacco ME, Ursini T, Striani P, Di Giammartino D, Paoloni M, Vallarola L, Pressanti GL, Fragassi G, Accorsi P, Manzoli L, Parruti G. High seroprevalence of HCV in the Abruzzo Region, Italy: results on a large sample from opt-out pre-surgical screening. Infection 2016;44:85-91. [PMID: 26363567 DOI: 10.1007/s15010-015-0841-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
85 Demetriou VL, Kostrikis LG. Molecular epidemiology of hepatitis C infection in Cyprus within the general population and high-risk cohorts. BMC Res Notes 2011;4:468. [PMID: 22040780 DOI: 10.1186/1756-0500-4-468] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
86 Neumann-Haefelin C, Timm J, Schmidt J, Kersting N, Fitzmaurice K, Oniangue-Ndza C, Kemper MN, Humphreys I, McKiernan S, Kelleher D, Lohmann V, Bowness P, Huzly D, Rosen HR, Kim AY, Lauer GM, Allen TM, Barnes E, Roggendorf M, Blum HE, Thimme R. Protective effect of human leukocyte antigen B27 in hepatitis C virus infection requires the presence of a genotype-specific immunodominant CD8+ T-cell epitope. Hepatology 2010;51:54-62. [PMID: 20034048 DOI: 10.1002/hep.23275] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 3.3] [Reference Citation Analysis]
87 European Union HCV Collaborators. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. Lancet Gastroenterol Hepatol 2017;2:325-36. [PMID: 28397696 DOI: 10.1016/S2468-1253(17)30045-6] [Cited by in Crossref: 145] [Cited by in F6Publishing: 60] [Article Influence: 29.0] [Reference Citation Analysis]
88 Saludes Montoro V, Ausina Ruiz V, Martró Català E. [Current options for predicting therapeutic response in chronically infected patients with hepatitis C virus genotype 1]. Enferm Infecc Microbiol Clin 2011;29 Suppl 5:51-8. [PMID: 22305670 DOI: 10.1016/S0213-005X(11)70044-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
89 Yan LB, Rao HY, Ma YJ, Bai L, Chen EQ, Du LY, Yang RF, Wei L, Tang H; CCgenos Study Group. Hepatitis B virus infection in Chinese patients with hepatitis C virus infection: prevalence, clinical characteristics, viral interactions and host genotypes: a nationwide cross-sectional study. BMJ Open. 2016;6:e012016. [PMID: 27733412 DOI: 10.1136/bmjopen-2016-012016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
90 Mariano A, Scalia Tomba G, Tosti ME, Spada E, Mele A. Estimating the incidence, prevalence and clinical burden of hepatitis C over time in Italy. Scand J Infect Dis. 2009;41:689-699. [PMID: 19579149 DOI: 10.1080/00365540903095358] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 3.3] [Reference Citation Analysis]
91 Navarro-de la Cruz D, Pérez-Castro S, Trigo-Daporta M, Aguilera-Guirao A. Prevalence and distribution of hepatitis C virus genotypes in Galicia during the period 2000-2015. Enferm Infecc Microbiol Clin (Engl Ed) 2019;37:256-9. [PMID: 29759421 DOI: 10.1016/j.eimc.2018.03.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
92 Petruzziello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol 2016; 22(34): 7824-7840 [PMID: 27678366 DOI: 10.3748/wjg.v22.i34.7824] [Cited by in CrossRef: 394] [Cited by in F6Publishing: 334] [Article Influence: 65.7] [Reference Citation Analysis]
93 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55:245-264. [PMID: 21371579 DOI: 10.1016/j.jhep.2011.02.023] [Cited by in Crossref: 847] [Cited by in F6Publishing: 805] [Article Influence: 77.0] [Reference Citation Analysis]
94 Ruta S, Cernescu C. Injecting drug use: A vector for the introduction of new hepatitis C virus genotypes. World J Gastroenterol 2015; 21(38): 10811-10823 [PMID: 26478672 DOI: 10.3748/wjg.v21.i38.10811] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
95 Larrubia JR, Lokhande MU, Moreno-Cubero E, García-Garzón S, Miquel J, Parra-Cid T, González-Praetorious A, Perna C, Lázaro A, Sanz-de-Villalobos E. HCV-specific CD8+ cell detection at week 12 of chronic hepatitis C treatment with PEG-interferon-α2b/ribavirin correlates with infection resolution. Cell Immunol. 2013;286:31-38. [PMID: 24287274 DOI: 10.1016/j.cellimm.2013.11.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
96 Kase K, Avi R, Toompere K, Rajasaar H, Pauskar M, Soodla P, Jõgeda EL, Zilmer K, Lutsar I, Huik K. Dynamics of hepatitis C epidemic among people living with HIV in Estonia based on Estonian HIV cohort study. BMC Infect Dis 2021;21:792. [PMID: 34376170 DOI: 10.1186/s12879-021-06521-w] [Reference Citation Analysis]
97 Vukobrat-Bijedic Z, Husic-Selimovic A, Mehinovic L, Mehmedovic A, Junuzovic D, Bjelogrlic I, Sofic A, Djurovic A. Analysis of effect of antiviral therapy on regression of liver fibrosis in patient with HCV infection. Mater Sociomed. 2014;26:172-176. [PMID: 25126010 DOI: 10.5455/msm.2014.26.172-176] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
98 Jatapai A, Nelson KE, Chuenchitra T, Kana K, Eiumtrakul S, Sunantarod E, Rangsin R. Prevalence and risk factors for hepatitis C virus infection among young Thai men. Am J Trop Med Hyg 2010;83:433-9. [PMID: 20682895 DOI: 10.4269/ajtmh.2010.09-0749] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
99 Jochem K, Leclerc P, Maurais E, Tremblay C, Cox J. Accuracy of physician reporting in routine public health surveillance for hepatitis C virus infection. Public Health Rep 2014;129:64-72. [PMID: 24381361 DOI: 10.1177/003335491412900110] [Reference Citation Analysis]
100 Marascio N, Matera G, Quirino A, Giancotti A, Barreca GS, Lamberti AG, Caroleo B, Liberto MC, Focà A. Eleven-year distribution pattern of hepatitis C virus in southern Italy. J Pathog. 2012;2012:631095. [PMID: 22934187 DOI: 10.1155/2012/631095] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
101 Gori A, Gheorgita S, Spinu C, Pinzaru I, Halacu A, Sajen O, Suveica L, Sausy A, Muller CP, Hübschen JM. Hepatitis B, C and D virus genotypes detected in HBsAg- or anti-HCV-positive people from the Republic of Moldova. Arch Virol 2018;163:431-8. [PMID: 29119358 DOI: 10.1007/s00705-017-3632-6] [Reference Citation Analysis]
102 Adriaenssens N, Coenen S, Kroes ACM, Versporten A, Vankerckhoven V, Muller A, Blix HS, Goossens H, Mittermayer H, Vaerenberg S, Markova B, Andrašević A, Kontemeniotis A, Vlček J, Frimodt-møller N, Rootslane L, Vuopio-varkila J, Cavalie P, Kern W, Giamarellou H, Ternák G, Briem H, Cunney R, Raz R, Folino P, Dumpis U, Valinteliene R, Bruch M, Borg M, Natsch S, Blix HS, Hryniewicz W, Ribeirinho M, Băicuş A, Ratchina S, Foltán V, Čižman M, Campos J, Skoog G, Zanetti G, Ünal S, Davey P; on behalf of the ESAC Project Group. European Surveillance of Antimicrobial Consumption (ESAC): systemic antiviral use in Europe. Journal of Antimicrobial Chemotherapy 2011;66:1897-905. [DOI: 10.1093/jac/dkr190] [Cited by in Crossref: 71] [Cited by in F6Publishing: 35] [Article Influence: 6.5] [Reference Citation Analysis]
103 Meier V, Ramadori G. Hepatitis C virus virology and new treatment targets. Expert Rev Anti Infect Ther 2009;7:329-50. [PMID: 19344246 DOI: 10.1586/eri.09.12] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
104 Obienu O, Nwokediuko S, Malu A, Lesi OA. Risk factors for hepatitis C virus transmission obscure in nigerian patients. Gastroenterol Res Pract 2011;2011:939673. [PMID: 21785583 DOI: 10.1155/2011/939673] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
105 Palmer BA, Menton J, Levis J, Kenny-walsh E, Crosbie O, Fanning LJ. The pan-genotype specificity of the hepatitis C virus anti-core monoclonal antibody C7-50 is contingent on the quasispecies profile of a population. Arch Virol 2012;157:2235-9. [DOI: 10.1007/s00705-012-1418-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
106 Wu J, Wang HL, Liu X, Ding C, Zhou Y, Fu X, Huang C, Zheng Y, Wang C, Li L, Yang S. Changing trends in viral hepatitis mortality in East and Southeast Asia between 1987 and 2015 and its prediction until 2030. Liver Int 2020;40:298-307. [PMID: 31674705 DOI: 10.1111/liv.14289] [Reference Citation Analysis]
107 Hartridge-Lambert SK, Stein EM, Markowitz AJ, Portlock CS. Hepatitis C and non-Hodgkin lymphoma: the clinical perspective. Hepatology. 2012;55:634-641. [PMID: 22120959 DOI: 10.1002/hep.25499] [Cited by in Crossref: 44] [Cited by in F6Publishing: 33] [Article Influence: 4.4] [Reference Citation Analysis]
108 De Vroey B, Moreno C, Laleman W, van Gossum M, Colle I, de Galocsy C, Langlet P, Robaeys G, Orlent H, Michielsen P. Hepatitis B virus and hepatitis C virus infections in Belgium: similarities and differences in epidemics and initial management. Eur J Gastroenterol Hepatol. 2013;25:613-619. [PMID: 23325285 DOI: 10.1097/meg.0b013e32835d83a2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
109 Avó AP, Agua-Doce I, Andrade A, Pádua E. Hepatitis C virus subtyping based on sequencing of the C/E1 and NS5B genomic regions in comparison to a commercially available line probe assay. J Med Virol 2013;85:815-22. [PMID: 23508907 DOI: 10.1002/jmv.23545] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 3.7] [Reference Citation Analysis]
110 Dearlove B, Wilson DJ. Coalescent inference for infectious disease: meta-analysis of hepatitis C. Philos Trans R Soc Lond B Biol Sci 2013;368:20120314. [PMID: 23382432 DOI: 10.1098/rstb.2012.0314] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
111 Brook G, Bhagani S, Kulasegaram R, Torkington A, Mutimer D, Hodges E, Hesketh L, Farnworth S, Sullivan V, Gore C, Devitt E, Sullivan AK; Clinical Effectiveness Group British Association for Sexual Health and HIV. United Kingdom National Guideline on the Management of the viral hepatitides A, B and C 2015. Int J STD AIDS 2016;27:501-25. [PMID: 26745988 DOI: 10.1177/0956462415624250] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
112 Pol S. A true revolution: enhanced motivation of the patient with rapid loss of virus (or rapid negativation of viral load), relationship between viral and histological cure. Clin Res Hepatol Gastroenterol 2011;35 Suppl 2:S43-5. [PMID: 22248693 DOI: 10.1016/S2210-7401(11)70006-7] [Reference Citation Analysis]
113 De Meyer S, Ghys A, Foster GR, Beumont M, Van Baelen B, Lin TI, Dierynck I, Ceulemans H, Picchio G. Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes. J Viral Hepat 2013;20:395-403. [PMID: 23647956 DOI: 10.1111/jvh.12046] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
114 Ohto H, Ishii T, Kitazawa J, Sugiyama S, Ujiie N, Fujimori K, Ariga H, Satoh T, Nollet KE, Okamoto H. Declining hepatitis C virus (HCV) prevalence in pregnant women: impact of anti-HCV screening of donated blood. Transfusion. 2010;50:693-700. [PMID: 19912584 DOI: 10.1111/j.1537-2995.2009.02487.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
115 Giugliano S, Oezkan F, Bedrejowski M, Kudla M, Reiser M, Viazov S, Scherbaum N, Roggendorf M, Timm J. Degree of cross-genotype reactivity of hepatitis C virus-specific CD8+ T cells directed against NS3. Hepatology 2009;50:707-16. [PMID: 19637188 DOI: 10.1002/hep.23096] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
116 Castro E, Roger E. Hepatitis C virus/human T lymphotropic virus 1/2 co-infection: Regional burden and virological outcomes in people who inject drugs. World J Virol 2016; 5(2): 68-72 [PMID: 27175351 DOI: 10.5501/wjv.v5.i2.68] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
117 Paraschiv S, Banica L, Nicolae I, Niculescu I, Abagiu A, Jipa R, Pineda-Peña AC, Pingarilho M, Neaga E, Theys K, Libin P, Otelea D, Abecasis A. Epidemic dispersion of HIV and HCV in a population of co-infected Romanian injecting drug users. PLoS One 2017;12:e0185866. [PMID: 29016621 DOI: 10.1371/journal.pone.0185866] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
118 Mansberg K, Kull K, Salupere R, Prükk T, Margus B, Kariis T, Remmel T, Suurmaa K, Ott K, Jaago K, Šmidt J. A Population-Based Surveillance Study on the Epidemiology of Hepatitis C in Estonia. Medicina (Kaunas) 2018;54:E9. [PMID: 30344240 DOI: 10.3390/medicina54010009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
119 Flisiak R, Halota W, Horban A, Juszczyk J, Pawlowska M, Simon K. Prevalence and risk factors of HCV infection in Poland. Eur J Gastroenterol Hepatol. 2011;23:1213-1217. [PMID: 22002000 DOI: 10.1097/meg.0b013e32834d173c] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 3.0] [Reference Citation Analysis]
120 Kang IJ, Wang LW, Yeh TK, Lee CC, Lee YC, Hsu SJ, Wu YS, Wang JC, Chao YS, Yueh A, Chern JH. Synthesis, activity, and pharmacokinetic properties of a series of conformationally-restricted thiourea analogs as novel hepatitis C virus inhibitors. Bioorg Med Chem 2010;18:6414-21. [PMID: 20675142 DOI: 10.1016/j.bmc.2010.07.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
121 Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis 2010;14:1-21, vii. [PMID: 20123436 DOI: 10.1016/j.cld.2009.11.009] [Cited by in Crossref: 276] [Cited by in F6Publishing: 239] [Article Influence: 23.0] [Reference Citation Analysis]
122 Paez Jimenez A, Mohamed MK, Eldin NS, Seif HA, El Aidi S, Sultan Y, Elsaid N, Rekacewicz C, El-Hoseiny M, El-Daly M. Injection drug use is a risk factor for HCV infection in urban Egypt. PLoS One. 2009;4:e7193. [PMID: 19784363 DOI: 10.1371/journal.pone.0007193] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
123 Gheorghe L, Rugină S, Dumitru IM, Franciuc I, Martinescu A, Balaş I. HLA class II alleles in Romanian patients with chronic hepatitis C. Germs 2015;5:44-9. [PMID: 26097834 DOI: 10.11599/germs.2015.1070] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
124 Werner CR, Schwarz JM, Egetemeyr DP, Beck R, Malek NP, Lauer UM, Berg CP. Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12. World J Gastroenterol 2016; 22(35): 8050-8059 [PMID: 27672299 DOI: 10.3748/wjg.v22.i35.8050] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 31] [Article Influence: 5.2] [Reference Citation Analysis]
125 European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2014;60:392-420. [PMID: 24331294 DOI: 10.1016/j.jhep.2013.11.003] [Cited by in Crossref: 600] [Cited by in F6Publishing: 564] [Article Influence: 66.7] [Reference Citation Analysis]
126 Nappi A, Perrella A, Bellopede P, Lanza A, Izzi A, Spatarella M, Sbreglia C. Safety of new DAAs for chronic HCV infection in a real life experience: role of a surveillance network based on clinician and hospital pharmacist. Infect Agent Cancer 2017;12:12. [PMID: 28191032 DOI: 10.1186/s13027-017-0119-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
127 Walewska-Zielecka B, Religioni U, Juszczyk G, Czerw A, Wawrzyniak Z, Soszyński P. Diagnosis of hepatitis C virus infection in pregnant women in the healthcare system in Poland: Is it worth the effort? Medicine (Baltimore) 2016;95:e4331. [PMID: 27472714 DOI: 10.1097/MD.0000000000004331] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
128 Liakina V, Valantinas J. Anti-HCV prevalence in the general population of Lithuania. Med Sci Monit 2012;18:PH28-35. [PMID: 22367136 DOI: 10.12659/msm.882511] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
129 Sadler MD, Lee SS. Revolution in hepatitis C antiviral therapy. Br Med Bull. 2015;113:31-44. [PMID: 25680808 DOI: 10.1093/bmb/ldv004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
130 Eriksen MB, Jørgensen LB, Krarup H, Laursen AL, Christensen PB, Møller A, Schlichting P, Kuiken C, Bukh J, Weis N; DANHEP Group. Molecular and epidemiological profiles of hepatitis C virus genotype 4 in Denmark. J Med Virol 2010;82:1869-77. [PMID: 20872713 DOI: 10.1002/jmv.21896] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
131 Tanase AM, Marchio A, Dumitrascu T, Dima S, Herlea V, Oprisan G, Dejean A, Popescu I, Pineau P. Mutation spectrum of hepatocellular carcinoma from eastern-European patients betrays the impact of a complex exposome. J Expo Sci Environ Epidemiol. 2015;25:256-263. [PMID: 24736102 DOI: 10.1038/jes.2014.16] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
132 Arain A, Robaeys G, Stöver H. Hepatitis C in European prisons: a call for an evidence-informed response. BMC Infect Dis 2014;14 Suppl 6:S17. [PMID: 25252822 DOI: 10.1186/1471-2334-14-S6-S17] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
133 Ciccozzi M, Equestre M, Costantino A, Marascio N, Quirino A, Lo Presti A, Cella E, Bruni R, Liberto MC, Focà A. Hepatitis C virus genotype 4d in Southern Italy: reconstruction of its origin and spread by a phylodynamic analysis. J Med Virol. 2012;84:1613-1619. [PMID: 22930510 DOI: 10.1002/jmv.23384] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
134 Paydas S. Hepatitis C virus and lymphoma. Crit Rev Oncol Hematol. 2015;93:246-256. [PMID: 25457774 DOI: 10.1016/j.critrevonc.2014.10.008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
135 Xu R, Yu Y, Leitch ECM, Wang M, Huang K, Huang J, Tang X, Liao Q, Song D, Shan Z, Li C, Mclauchlan J, Rong X. HCV genotype 6 prevalence, spontaneous clearance and diversity among elderly members of the Li ethnic minority in Baisha County, China. J Viral Hepat 2019;26:529-40. [PMID: 30629794 DOI: 10.1111/jvh.13062] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
136 Valery PC, Laversanne M, Clark PJ, Petrick JL, McGlynn KA, Bray F. Projections of primary liver cancer to 2030 in 30 countries worldwide. Hepatology. 2018;67:600-611. [PMID: 28859220 DOI: 10.1002/hep.29498] [Cited by in Crossref: 75] [Cited by in F6Publishing: 79] [Article Influence: 15.0] [Reference Citation Analysis]
137 Hahné SJ, Veldhuijzen IK, Wiessing L, Lim TA, Salminen M, Laar Mv. Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening. BMC Infect Dis. 2013;13:181. [PMID: 23597411 DOI: 10.1186/1471-2334-13-181] [Cited by in Crossref: 142] [Cited by in F6Publishing: 136] [Article Influence: 15.8] [Reference Citation Analysis]
138 Ebranati E, Mancon A, Airoldi M, Renica S, Shkjezi R, Dragusha P, Della Ventura C, Ciccaglione AR, Ciccozzi M, Bino S, Tanzi E, Micheli V, Riva E, Galli M, Zehender G. Time and Mode of Epidemic HCV-2 Subtypes Spreading in Europe: Phylodynamics in Italy and Albania. Diagnostics (Basel) 2021;11:327. [PMID: 33671355 DOI: 10.3390/diagnostics11020327] [Reference Citation Analysis]
139 Patel JH, Cobbold JF, Thomas HC, Taylor-Robinson SD. Hepatitis C and hepatic steatosis. QJM. 2010;103:293-303. [PMID: 20139103 DOI: 10.1093/qjmed/hcp192] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
140 Viazov S, Ross SS, Kyuregyan KK, Timm J, Neumann-Haefelin C, Isaeva OV, Popova OE, Dmitriev PN, El Sharkawi F, Thimme R, Michailov MI, Roggendorf M. Hepatitis C virus recombinants are rare even among intravenous drug users. J Med Virol 2010;82:232-8. [PMID: 20029799 DOI: 10.1002/jmv.21631] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
141 Machado MV, Oliveira AG, Cortez-pinto H. Hepatic steatosis in patients coinfected with human immunodeficiency virus/hepatitis C virus: A meta-analysis of the risk factors. Hepatology 2010;52:71-8. [DOI: 10.1002/hep.23619] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 2.9] [Reference Citation Analysis]
142 Khaled H, Abu-Taleb F, Haggag R. Hepatitis C virus and non-Hodgkin's lymphomas: A minireview. J Adv Res 2017;8:131-7. [PMID: 28149648 DOI: 10.1016/j.jare.2016.11.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
143 Cannalire R, Barreca ML, Manfroni G, Cecchetti V. A Journey around the Medicinal Chemistry of Hepatitis C Virus Inhibitors Targeting NS4B: From Target to Preclinical Drug Candidates. J Med Chem 2016;59:16-41. [PMID: 26241789 DOI: 10.1021/acs.jmedchem.5b00825] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
144 Mancusi RL, Andreoni M, d'Angela D, Sarrecchia C, Spandonaro F. Epidemiological burden estimates for pathologies with a nonconstant risk: an application to HCV in Italy according to age, Metavir score, and genotype: A systematic review and meta-analysis. Medicine (Baltimore) 2016;95:e5143. [PMID: 27759643 DOI: 10.1097/MD.0000000000005143] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
145 Hofstraat SHI, Falla AM, Duffell EF, Hahné SJM, Amato-Gauci AJ, Veldhuijzen IK, Tavoschi L. Current prevalence of chronic hepatitis B and C virus infection in the general population, blood donors and pregnant women in the EU/EEA: a systematic review. Epidemiol Infect 2017;145:2873-85. [PMID: 28891457 DOI: 10.1017/S0950268817001947] [Cited by in Crossref: 50] [Cited by in F6Publishing: 32] [Article Influence: 10.0] [Reference Citation Analysis]
146 Papastergiou V, Karatapanis S. Current status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6. World J Clin Cases 2015; 3(3): 210-220 [PMID: 25789294 DOI: 10.12998/wjcc.v3.i3.210] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
147 Mühlberger N, Schwarzer R, Lettmeier B, Sroczynski G, Zeuzem S, Siebert U. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health. 2009;9:34. [PMID: 19161623 DOI: 10.1186/1471-2458-9-34] [Cited by in Crossref: 151] [Cited by in F6Publishing: 137] [Article Influence: 11.6] [Reference Citation Analysis]
148 Warren RB, Al-Rifai A. Treatment of severe psoriasis with biological therapies in patients with viral hepatitis B and C. Br J Dermatol. 2013;168:461-462. [PMID: 23445306 DOI: 10.1111/bjd.12227] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
149 Giménez-Manzorro Á, García-González X, Rodríguez-González CG, Ochoa-Palominos A, Sanjurjo-Sáez M, Clemente-Ricote G. [Cost-effectiveness and safety of telaprevir and boceprevir for chronic hepatitis C in real-world clinical practice]. Gastroenterol Hepatol 2015;38:575-82. [PMID: 26321320 DOI: 10.1016/j.gastrohep.2015.07.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
150 Kopilović B, Poljak M, Seme K, Klavs I. Hepatitis C virus infection among pregnant women in Slovenia: study on 31,849 samples obtained in four screening rounds during 1999, 2003, 2009 and 2013. Euro Surveill 2015;20:21144. [PMID: 26062646 DOI: 10.2807/1560-7917.es2015.20.22.21144] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
151 Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61:77-87. [PMID: 25069599 DOI: 10.1002/hep.27259] [Cited by in Crossref: 957] [Cited by in F6Publishing: 866] [Article Influence: 119.6] [Reference Citation Analysis]
152 Khyatti M, Trimbitas RD, Zouheir Y, Benani A, El Messaoudi MD, Hemminki K. Infectious diseases in North Africa and North African immigrants to Europe. Eur J Public Health 2014;24 Suppl 1:47-56. [PMID: 25107998 DOI: 10.1093/eurpub/cku109] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
153 Yan Z, Fan K, Wang Y, Fan Y, Tan Z, Deng G. Changing pattern of clinical epidemiology on hepatitis C virus infection in southwest china. Hepat Mon 2012;12:196-204. [PMID: 22550528 DOI: 10.5812/hepatmon.857] [Cited by in F6Publishing: 19] [Reference Citation Analysis]
154 Tınazlı M, Güvenir M, Aykaç A, Süer K. Hepatitis C virus infection among patients admitted to a rheumatology ward in northern Cyprus. The Egyptian Rheumatologist 2017;39:245-7. [DOI: 10.1016/j.ejr.2017.04.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
155 Kielland KB, Skaug K, Amundsen EJ, Dalgard O. All-cause and liver-related mortality in hepatitis C infected drug users followed for 33 years: a controlled study. J Hepatol. 2013;58:31-37. [PMID: 22960427 DOI: 10.1016/j.jhep.2012.08.024] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 4.3] [Reference Citation Analysis]
156 Cornberg M, Razavi HA, Alberti A, Bernasconi E, Buti M, Cooper C, Dalgard O, Dillion JF, Flisiak R, Forns X, Frankova S, Goldis A, Goulis I, Halota W, Hunyady B, Lagging M, Largen A, Makara M, Manolakopoulos S, Marcellin P, Marinho RT, Pol S, Poynard T, Puoti M, Sagalova O, Sibbel S, Simon K, Wallace C, Young K, Yurdaydin C, Zuckerman E, Negro F, Zeuzem S. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int. 2011;31 Suppl 2:30-60. [PMID: 21651702 DOI: 10.1111/j.1478-3231.2011.02539.x] [Cited by in Crossref: 272] [Cited by in F6Publishing: 255] [Article Influence: 24.7] [Reference Citation Analysis]
157 Demetriou VL, van de Vijver DA, Kostrikis LG. Molecular epidemiology of hepatitis C infection in Cyprus: evidence of polyphyletic infection. J Med Virol. 2009;81:238-248. [PMID: 19107977 DOI: 10.1002/jmv.21370] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.0] [Reference Citation Analysis]
158 Santantonio T, Wiegand J, Gerlach JT. Acute hepatitis C: current status and remaining challenges. J Hepatol. 2008;49:625-633. [PMID: 18706735 DOI: 10.1016/j.jhep.2008.07.005] [Cited by in Crossref: 97] [Cited by in F6Publishing: 79] [Article Influence: 6.9] [Reference Citation Analysis]
159 Manuylov VA, Chub EV, Kichatova VS, Soboleva NV, Isaeva OV, Zamyatnin AA Jr, Netesov SV. Hepatitis C virus subtype 3a was introduced in the USSR in the early 1980s. J Gen Virol 2017;98:2079-87. [PMID: 28742003 DOI: 10.1099/jgv.0.000878] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
160 Park JH, Jee MH, Kwon OS, Keum SJ, Jang SK. Infectivity of hepatitis C virus correlates with the amount of envelope protein E2: development of a new aptamer-based assay system suitable for measuring the infectious titer of HCV. Virology 2013;439:13-22. [PMID: 23485371 DOI: 10.1016/j.virol.2013.01.014] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
161 Chouikha A, Khedhiri M, Triki H, Hammemi W, Sadraoui A, Touzi H, Ben Yahia A, Chtourou A, Gargouri S, Feki Ben Rajah L, Hakim Karray H, Triki H. Focus on hepatitis C virus genotype distribution in Tunisia prior to elimination: a 16-year retrospective study. Arch Virol 2021;166:501-10. [PMID: 33394169 DOI: 10.1007/s00705-020-04918-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
162 Giannini EG, Basso M, Savarino V, Picciotto A. Predictive factors for response to peginterferon-alpha and ribavirin treatment of chronic HCV infection in patients aged 65 years and more. Dig Dis Sci 2010;55:3193-9. [PMID: 20848200 DOI: 10.1007/s10620-010-1408-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
163 Huang RY, Chang HT, Lan CY, Pai TW, Wu CN, Ling CM, Chang MD. Development and evaluation of a sensitive enzyme-linked oligonucleotide-sorbent assay for detection of polymerase chain reaction-amplified hepatitis C virus of genotypes 1-6. J Virol Methods 2008;151:211-6. [PMID: 18565599 DOI: 10.1016/j.jviromet.2008.05.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
164 Kim JY, Cho J, Hwang SH, Kil H, Bae SH, Kim YS, Lee HC, Jeong SH. Behavioral and healthcare-associated risk factors for chronic hepatitis C virus infection in Korea. J Korean Med Sci 2012;27:1371-7. [PMID: 23166420 DOI: 10.3346/jkms.2012.27.11.1371] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
165 Bouacida L, Suin V, Hutse V, Boudewijns M, Cartuyvels R, Debaisieux L, De Laere E, Hallin M, Hougardy N, Lagrou K, Oris E, Padalko E, Reynders M, Roussel G, Senterre JM, Stalpaert M, Ursi D, Vael C, Vaira D, Van Acker J, Verstrepen W, Van Gucht S, Kabamba B, Quoilin S, Muyldermans G. Distribution of HCV genotypes in Belgium from 2008 to 2015. PLoS One 2018;13:e0207584. [PMID: 30517127 DOI: 10.1371/journal.pone.0207584] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
166 Çetin Duran A, Kaya Çetinkaya Ö, Sayıner AA, Şeydaoğlu G, Özkarataş E, Abacıoğlu H. Changes on Hepatitis C virus genotype distribution in Western Turkey: Evaluation of twelve-year data. Turk J Gastroenterol 2020;31:128-35. [PMID: 32141821 DOI: 10.5152/tjg.2020.18798] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
167 Germano FN, dos Santos CA, Honscha G, Strasburg A, Gabbi B, Mendoza-Sassi RA, Soares EA, Seuánez HN, Soares MA, Martínez AM. Prevalence of hepatitis C virus among users attending a voluntary testing centre in Rio Grande, southern Brazil: predictive factors and hepatitis C virus genotypes. Int J STD AIDS 2010;21:466-71. [PMID: 20852195 DOI: 10.1258/ijsa.2009.009089] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
168 Schütte K, Kipper M, Kahl S, Bornschein J, Götze T, Adolf D, Arend J, Seidensticker R, Lippert H, Ricke J. Clinical characteristics and time trends in etiology of hepatocellular cancer in Germany. Digestion. 2013;87:147-159. [PMID: 23548687 DOI: 10.1159/000346743] [Cited by in Crossref: 17] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
169 Pol S, Corouge M. Treatment of hepatitis C: perspectives. Med Mal Infect. 2014;44:449-454. [PMID: 25174659 DOI: 10.1016/j.medmal.2014.07.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
170 Vučetić D, Kecman G, Ilić V, Balint B. Blood donors' positivity for transfusion-transmissible infections: the Serbian Military Medical Academy experience. Blood Transfus 2015;13:569-75. [PMID: 26057495 DOI: 10.2450/2015.0314-14] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
171 Aghemo A, Rumi MG, Colombo M. Pegylated interferons alpha2a and alpha2b in the treatment of chronic hepatitis C. Nat Rev Gastroenterol Hepatol 2010;7:485-94. [PMID: 20644567 DOI: 10.1038/nrgastro.2010.101] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 3.7] [Reference Citation Analysis]
172 Demetriou VL, Kostrikis LG. Near-full genome characterization of unclassified hepatitis C virus strains relating to genotypes 1 and 4. J Med Virol 2011;83:2119-27. [PMID: 22012719 DOI: 10.1002/jmv.22237] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
173 Samimi-Rad K, Nasiri Toosi M, Masoudi-Nejad A, Najafi A, Rahimnia R, Asgari F, Shabestari AN, Hassanpour G, Alavian SM, Asgari F. Molecular epidemiology of hepatitis C virus among injection drug users in Iran: a slight change in prevalence of HCV genotypes over time. Arch Virol 2012;157:1959-65. [PMID: 22695769 DOI: 10.1007/s00705-012-1369-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
174 Zamani F, Sohrabi M, Poustchi H, Keyvani H, Saeedian FS, Ajdarkosh H, Khoonsari M, Hemmasi G, Moradilakeh M, Motamed N, Maadi M. Prevalence and risk factors of hepatitis C virus infection in amol city, north of iran: a population-based study (2008-2011). Hepat Mon 2013;13:e13313. [PMID: 24358039 DOI: 10.5812/hepatmon.13313] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
175 Cozzolongo R, Osella AR, Elba S, Petruzzi J, Buongiorno G, Giannuzzi V, Leone G, Bonfiglio C, Lanzilotta E, Manghisi OG. Epidemiology of HCV infection in the general population: a survey in a southern Italian town. Am J Gastroenterol. 2009;104:2740-2746. [PMID: 19638964 DOI: 10.1038/ajg.2009.428] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 4.2] [Reference Citation Analysis]
176 Coppola N, Alessio L, Onorato L, Sagnelli C, Macera M, Sagnelli E, Pisaturo M. Epidemiology and management of hepatitis C virus infections in immigrant populations. Infect Dis Poverty 2019;8:17. [PMID: 30871599 DOI: 10.1186/s40249-019-0528-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
177 Indolfi G, Bailey H, Serranti D, Giaquinto C, Thorne C; PENTAHep Study Group. Treatment and monitoring of children with chronic hepatitis C in the Pre-DAA era: A European survey of 38 paediatric specialists. J Viral Hepat. 2019;26:961-968. [PMID: 30980773 DOI: 10.1111/jvh.13111] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
178 Vriend HJ, Op de Coul EL, van de Laar TJ, Urbanus AT, van der Klis FR, Boot HJ. Hepatitis C virus seroprevalence in the Netherlands. Eur J Public Health 2012;22:819-21. [PMID: 22461704 DOI: 10.1093/eurpub/cks013] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
179 Monari M, Foglia E, Montanelli A, Assandri R, Lagioia M, Ferrario L, Garagiola E, Porazzi E, Croce D. Economic, organizational and budget impact of a new diagnostic plan for HCV detection: what’s “new”? Riv Ital Med Lab 2015;11:236-42. [DOI: 10.1007/s13631-015-0098-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
180 Marcellusi A, Viti R, Capone A, Mennini FS. Costi diretti e indiretti assorbiti dalle patologie HCV-indotte in Italia: stima basata su una metodologia probabilistica di Cost of Illness. PharmacoEcon Ital Res Artic 2014;16. [DOI: 10.1007/s40276-014-0023-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
181 Szabo SM, Samp JC, Walker DR, Lane S, Cline SK, Gooch KL, Jimenez-mendez R, Levy AR. Liver-specific case fatality due to chronic hepatitis C virus infection: A systematic review. Annals of Hepatology 2015;14:618-30. [DOI: 10.1016/s1665-2681(19)30756-2] [Cited by in Crossref: 6] [Article Influence: 0.9] [Reference Citation Analysis]
182 Abdel-Razek W, Waked I. Optimal therapy in genotype 4 chronic hepatitis C: finally cured? Liver Int. 2015;35 Suppl 1:27-34. [PMID: 25529085 DOI: 10.1111/liv.12724] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
183 Saludes V, Bracho MA, Valero O, Ardèvol M, Planas R, González-Candelas F, Ausina V, Martró E. Baseline prediction of combination therapy outcome in hepatitis C virus 1b infected patients by discriminant analysis using viral and host factors. PLoS One 2010;5:e14132. [PMID: 21152430 DOI: 10.1371/journal.pone.0014132] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
184 Llewellyn A, Faria R, Woods B, Simmonds M, Lomas J, Woolacott N, Griffin S. Daclatasvir for the Treatment of Chronic Hepatitis C: A Critique of the Clinical and Economic Evidence. Pharmacoeconomics 2016;34:981-92. [PMID: 27278217 DOI: 10.1007/s40273-016-0418-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
185 Weil C, Nwankwo C, Friedman M, Kenet G, Chodick G, Shalev V. Epidemiology of hepatitis C virus infection in a large Israeli health maintenance organization: Epidemiology of Hepatitis C in a large Israeli HMO. J Med Virol 2016;88:1044-50. [DOI: 10.1002/jmv.24426] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
186 Marascio N, Torti C, Liberto M, Focà A. Update on different aspects of HCV variability: focus on NS5B polymerase. BMC Infect Dis 2014;14 Suppl 5:S1. [PMID: 25234810 DOI: 10.1186/1471-2334-14-S5-S1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
187 Stöver H, Hariga F. Prison-based needle and syringe programmes (PNSP) – Still highly controversial after all these years. Drugs: Education, Prevention and Policy 2016;23:103-12. [DOI: 10.3109/09687637.2016.1148117] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
188 Calado RA, Rocha MR, Parreira R, Piedade J, Venenno T, Esteves A. Hepatitis C virus subtypes circulating among intravenous drug users in Lisbon, Portugal. J Med Virol. 2011;83:608-615. [PMID: 21328374 DOI: 10.1002/jmv.21955] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
189 Gheorghe L, Iacob S, Csiki IE. Prevalence of hepatitis C in Romania: Different from European rates? Journal of Hepatology 2008;49:661-2. [DOI: 10.1016/j.jhep.2008.06.016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
190 Sharma SA, Feld JJ. Acute Hepatitis C: Management in the Rapidly Evolving World of HCV. Curr Gastroenterol Rep 2014;16. [DOI: 10.1007/s11894-014-0371-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
191 Edmunds BL, Miller ER, Tsourtos G. The distribution and socioeconomic burden of Hepatitis C virus in South Australia: a cross-sectional study 2010-2016. BMC Public Health 2019;19:527. [PMID: 31068170 DOI: 10.1186/s12889-019-6847-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
192 Matas M, Picornell A, Cifuentes C, Payeras A, Bassa A, Homar F, González-Candelas F, López-Labrador FX, Moya A, Ramon MM, Castro JA. Generalized Linear Model (GLM) framework for the association of host variables and viral strains with liver fibrosis in HCV/HIV coinfected patients. Infect Genet Evol 2013;13:284-91. [PMID: 23174528 DOI: 10.1016/j.meegid.2012.10.020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
193 Olsen K, Dahl PE, Paulssen EJ, Husebekk A, Widell A, Busund R. Increased risk of transmission of hepatitis C in open heart surgery compared with vascular and pulmonary surgery. Ann Thorac Surg 2010;90:1425-31. [PMID: 20971233 DOI: 10.1016/j.athoracsur.2010.06.053] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
194 Ramia S, Melhem NM, Kreidieh K. Hepatitis C virus infection in the Middle East and North Africa “MENA” region: injecting drug users (IDUs) is an under-investigated population. Infection. 2012;40:1-10. [PMID: 22237470 DOI: 10.1007/s15010-011-0236-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
195 El-Shabrawi MH, Kamal NM. Burden of pediatric hepatitis C. World J Gastroenterol 2013; 19(44): 7880-7888 [PMID: 24307782 DOI: 10.3748/wjg.v19.i44.7880] [Cited by in CrossRef: 80] [Cited by in F6Publishing: 66] [Article Influence: 8.9] [Reference Citation Analysis]
196 Martinello M, Matthews GV. Enhancing the detection and management of acute hepatitis C virus infection. Int J Drug Policy 2015;26:899-910. [PMID: 26254495 DOI: 10.1016/j.drugpo.2015.07.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
197 Ansaldi F, Orsi A, Sticchi L, Bruzzone B, Icardi G. Hepatitis C virus in the new era: Perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. World J Gastroenterol 2014; 20(29): 9633-9652 [PMID: 25110404 DOI: 10.3748/wjg.v20.i29.9633] [Cited by in CrossRef: 96] [Cited by in F6Publishing: 81] [Article Influence: 12.0] [Reference Citation Analysis]
198 Smith KJ, Norris S, O'Farrelly C, O'Mara SM. Risk factors for the development of depression in patients with hepatitis C taking interferon-α. Neuropsychiatr Dis Treat. 2011;7:275-292. [PMID: 21654873 DOI: 10.2147/NDT.S13917] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
199 Kiprijanovska S, Davalieva K, Noveski P, Sukarova-Stefanovska E, Plaseska-Karanfilska D. Prevalence of hepatitis C virus genotypes in risk groups in the Republic of Macedonia: a 5 years survey. J Med Virol. 2013;85:2072-2078. [PMID: 23959998 DOI: 10.1002/jmv.23706] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
200 Johnson SJ, Parisé H, Virabhak S, Filipovic I, Samp JC, Misurski D. Economic evaluation of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic genotype 1 hepatitis c virus infection. J Med Econ 2016;19:983-94. [PMID: 27172133 DOI: 10.1080/13696998.2016.1189920] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
201 Seme K, Vrhovac M, Mocilnik T, Maticic M, Lesnicar G, Baklan Z, Volkar JM, Rajter M, Stepec S, Lunar M, Poljak M. Hepatitis C virus genotypes in 1,504 patients in Slovenia, 1993-2007. J Med Virol 2009;81:634-9. [PMID: 19235845 DOI: 10.1002/jmv.21427] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
202 Farrell G, Fan J. Prevention of Hepatocellular Carcinoma. In: Al Knawy B, Reddy K, Bolondi L, editors. Hepatocellular Carcinoma. CRC Press; 2009. pp. 36-61. [DOI: 10.3109/9780203092880-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
203 Sagnelli E, Sagnelli C, Russo A, Pisaturo M, Camaioni C, Astorri R, Coppola N. Impact of DAA-Based Regimens on HCV-Related Extra-Hepatic Damage: A Narrative Review. Adv Exp Med Biol 2021;1323:115-47. [PMID: 33326112 DOI: 10.1007/5584_2020_604] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
204 Maticic M. A national multidisciplinary healthcare network for treatment of hepatitis C in people who inject drugs in Slovenia. BMC Infect Dis 2014;14 Suppl 6:S6. [PMID: 25253513 DOI: 10.1186/1471-2334-14-S6-S6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
205 Grandal M, Pernas B, Mariño A, Álvarez H, Tabernilla A, Castro-Iglesias Á, Mena Á, Delgado M, Pértega S, Poveda E. Characterization of chronic HCV infection in Northwest Spain: Impact of the treatment strategic plan of the Spanish National Health Service on HCV cure. J Med Virol 2017;89:1304-8. [PMID: 28079256 DOI: 10.1002/jmv.24766] [Reference Citation Analysis]
206 Rodríguez-Osorio I, Cid P, Morano L, Castro Á, Suárez M, Delgado M, Margusino L, Meijide H, Pernas B, Tabernilla A, Pedreira JD, Mena Á, Poveda E. Real life experience with direct-acting antivirals agents against hepatitis C infection in elderly patients. J Clin Virol. 2017;88:58-61. [PMID: 28183063 DOI: 10.1016/j.jcv.2017.01.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
207 Keten D, Emin Ova M, Sirri Keten H, Keten A, Gulderen E, Tumer S, Caliskan A, Kulotu S. The Prevalence of Hepatitis B and C Among Prisoners in Kahramanmaras, Turkey. Jundishapur J Microbiol 2016;9:e31598. [PMID: 27127594 DOI: 10.5812/jjm.31598] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
208 Pol S. Virus de l’hépatite C: 25 ans, la fin de l’histoire ? Med Sci (Paris) 2013;29:998-1003. [DOI: 10.1051/medsci/20132911016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
209 Li C, Yuan M, Lu L, Lu T, Xia W, Pham VH, Vo AXD, Nguyen MH, Abe K. The genetic diversity and evolutionary history of hepatitis C virus in Vietnam. Virology 2014;468-470:197-206. [PMID: 25193655 DOI: 10.1016/j.virol.2014.07.026] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
210 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol 2014;20:89-136. [PMID: 25032178 DOI: 10.3350/cmh.2014.20.2.89] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
211 Leone G, Larocca LM, Pizzigallo E. Introducing mediterranean journal of hematology and infectious diseases. Mediterr J Hematol Infect Dis 2009;1:e2009001. [PMID: 21415983 DOI: 10.4084/MJHID.2009.001] [Reference Citation Analysis]
212 Iqbal S, Yousuf MH, Yousaf MI. Dramatic response of hepatitis C patients chronically infected with hepatitis C virus genotype 3 to sofosbuvir-based therapies in Punjab, Pakistan: A prospective study. World J Gastroenterol 2017; 23(44): 7899-7905 [PMID: 29209131 DOI: 10.3748/wjg.v23.i44.7899] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
213 Buti M, Esteban R. Hepatitis C virus genotype 3: a genotype that is not ‘easy-to-treat’. Expert Rev Gastroenterol Hepatol. 2015;9:375-385. [PMID: 25222289 DOI: 10.1586/17474124.2015.960396] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
214 Walker A, Skibbe K, Steinmann E, Pfaender S, Kuntzen T, Megger DA, Groten S, Sitek B, Lauer GM, Kim AY, Pietschmann T, Allen TM, Timm J. Distinct Escape Pathway by Hepatitis C Virus Genotype 1a from a Dominant CD8+ T Cell Response by Selection of Altered Epitope Processing. J Virol 2016;90:33-42. [PMID: 26446603 DOI: 10.1128/JVI.01993-15] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
215 Di Lello FA, Farias AA, Culasso AC, Pérez PS, Pisano MB, Contigiani MS, Campos RH, Ré VE. Changing epidemiology of hepatitis C virus genotypes in the central region of Argentina. Arch Virol 2015;160:909-15. [PMID: 25762309 DOI: 10.1007/s00705-015-2390-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
216 Oliveira ML, Yoshida CF, Telles PR, Hacker MA, Oliveira SA, Miguel JC, do O KM, Bastos FI. Trends in HCV prevalence, risk factors and distribution of viral genotypes in injecting drug users: findings from two cross-sectional studies. Epidemiol Infect. 2009;137:970-979. [PMID: 19144250 DOI: 10.1017/s0950268808001970] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
217 Corstjens PL, Abrams WR, Malamud D. Saliva and viral infections. Periodontol 2000 2016;70:93-110. [PMID: 26662485 DOI: 10.1111/prd.12112] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 8.8] [Reference Citation Analysis]
218 Rivero-Juarez A, Gutierrez-Valencia A, Castaño M, Merino D, Neukam K, Ríos-Villegas MJ, Lopez-Ruz MA, Jiménez-Aguilar P, Marquez M, Collado A, Gomez-Vidal A, Hernandez-Quero J, Tellez F, Fernandez-Fuertes E, Rivero A, López-Cortés LF; Group for the Study of Viral Hepatitis (HEPAVIR) of the Andalusian Society of Infectious Diseases (SAEI). Dimension of chronic hepatitis C virus in HIV-infected patients in the interferon-free era: an overview from south Spain. Eur J Clin Microbiol Infect Dis 2015;34:2247-55. [PMID: 26342330 DOI: 10.1007/s10096-015-2476-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
219 Melo IC, Ferraz ML, Perez RM, Emori CT, Uehara SN, de Carvalho-Filho RJ, Silva AE, de Souza e Silva IS. Do differences exist between chronic hepatitis C genotypes 2 and 3? Rev Soc Bras Med Trop 2014;47:143-8. [PMID: 24861286 DOI: 10.1590/0037-8682-0269-2013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
220 de Leuw P, Sarrazin C, Zeuzem S. How to use virological tools for the optimal management of chronic hepatitis C: Virological diagnostics in HCV. Liver International 2011;31:3-12. [DOI: 10.1111/j.1478-3231.2010.02398.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
221 de Bruijne J, Weegink CJ, Jansen PL, Reesink HW. New developments in the antiviral treatment of hepatitis C. Vox Sang. 2009;97:1-12. [PMID: 19392783 DOI: 10.1111/j.1423-0410.2009.01187.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
222 Marco A, Gallego C, Caylà JA. Incidence of hepatitis C infection among prisoners by routine laboratory values during a 20-year period. PLoS One 2014;9:e90560. [PMID: 24587394 DOI: 10.1371/journal.pone.0090560] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
223 Heidrich B, Cetindere A, Beyaz M, Stahmeyer JT, Basaran MM, Braynis B, Raupach R, Bremer B, Manns MP, Wedemeyer H, Bastürk M. High prevalence of hepatitis markers in immigrant populations: a prospective screening approach in a real-world setting. Eur J Gastroenterol Hepatol 2014;26:1090-7. [PMID: 25076065 DOI: 10.1097/MEG.0000000000000164] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
224 Manos MM, Shvachko VA, Murphy RC, Arduino JM, Shire NJ. Distribution of hepatitis C virus genotypes in a diverse US integrated health care population. J Med Virol. 2012;84:1744-1750. [PMID: 22997077 DOI: 10.1002/jmv.23399] [Cited by in Crossref: 58] [Cited by in F6Publishing: 58] [Article Influence: 6.4] [Reference Citation Analysis]
225 Kartashev V, Döring M, Nieto L, Coletta E, Kaiser R, Sierra S, Guerrero A, Stoiber H, Paar C, Vandamme A, Nevens F, Ranst MV, Cuypers L, Braun P, Ehret R, Obermeier M, Schneeweiss S, Scholten S, Römer K, Isernhagen K, Qurashi N, Heger E, Knops E, Neumann-fraune M, Timm J, Walker A, Lübke N, Wedemeyer H, Wiesch JSZ, Lütgehetmann M, Polywka S, Däumer M, Hoffmann D, Protzer U, Marascio N, Foca A, Liberto M, Barreca G, Galati L, Torti C, Pisani V, Perno C, Ceccherini-silberstein F, Cento V, Ciotti M, Zazzi M, Rossetti B, Luca A, Caudai C, Mor O, Devaux C, Staub T, Araujo F, Gomes P, Cabanas J, Markin N, Khomenko I, Govorukhina M, Lugovskaya G, Dontsov D, Mas A, Martró E, Saludes V, Rodríguez-frías F, García F, Casas P, Iglesia ADL, Alados J, Pena-lópez M, Rodríguez M, Galán J, Suárez A, Cardeñoso L, Guerrero M, Vegas-dominguez C, Blas-espada J, García R, García-bujalance S, Benítez-gutiérrez L, Mendoza CD, Montiel N, Santos J, Viciana I, Delgado A, Martínez-sanchez P, Fernández-alonso M, Reina G, Trigo M, Echeverría M, Aguilera A, Navarro D, Bernal S, Lozano M, Fernández-cuenca F, Orduña A, Eiros J, Lejarazu ROD, Martínez-sapiña A, García-díaz A, Haque T. New findings in HCV genotype distribution in selected West European, Russian and Israeli regions. Journal of Clinical Virology 2016;81:82-9. [DOI: 10.1016/j.jcv.2016.05.010] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 7.3] [Reference Citation Analysis]
226 Laheij AM, Kistler JO, Belibasakis GN, Välimaa H, de Soet JJ; European Oral Microbiology Workshop (EOMW) 2011. Healthcare-associated viral and bacterial infections in dentistry. J Oral Microbiol 2012;4. [PMID: 22701774 DOI: 10.3402/jom.v4i0.17659] [Cited by in Crossref: 51] [Cited by in F6Publishing: 37] [Article Influence: 5.1] [Reference Citation Analysis]
227 Vilibic-Cavlek T, Kucinar J, Kaic B, Vilibic M, Pandak N, Barbic L, Stevanovic V, Vranes J. Epidemiology of hepatitis C in Croatia in the European context. World J Gastroenterol 2015; 21(32): 9476-9493 [PMID: 26327756 DOI: 10.3748/wjg.v21.i32.9476] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
228 Nyanguile O, Devogelaere B, Vijgen L, Van den Broeck W, Pauwels F, Cummings MD, De Bondt HL, Vos AM, Berke JM, Lenz O, Vandercruyssen G, Vermeiren K, Mostmans W, Dehertogh P, Delouvroy F, Vendeville S, VanDyck K, Dockx K, Cleiren E, Raboisson P, Simmen KA, Fanning GC. 1a/1b subtype profiling of nonnucleoside polymerase inhibitors of hepatitis C virus. J Virol 2010;84:2923-34. [PMID: 20071590 DOI: 10.1128/JVI.01980-09] [Cited by in Crossref: 35] [Cited by in F6Publishing: 15] [Article Influence: 2.9] [Reference Citation Analysis]
229 Fevery B, Verbinnen T, Peeters M, Janssen K, Witek J, Jessner W, De Meyer S, Lenz O. Virology analyses of HCV genotype 4 isolates from patients treated with simeprevir and peginterferon/ribavirin in the Phase III RESTORE study. J Viral Hepat 2017;24:28-36. [PMID: 27696653 DOI: 10.1111/jvh.12614] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
230 Ross RS, Stambouli O, Grüner N, Marcus U, Cai W, Zhang W, Zimmermann R, Roggendorf M. Detection of infections with hepatitis B virus, hepatitis C virus, and human immunodeficiency virus by analyses of dried blood spots--performance characteristics of the ARCHITECT system and two commercial assays for nucleic acid amplification. Virol J. 2013;10:72. [PMID: 23497102 DOI: 10.1186/1743-422x-10-72] [Cited by in Crossref: 53] [Cited by in F6Publishing: 29] [Article Influence: 5.9] [Reference Citation Analysis]
231 Fecury AA, Almeida MK, Santos KN, Freitas Ada S, Dantas Sde F, Costa CA, Crescente ÂB, Sousa RC, Brito EB, Nassiri R, Lampe E, Martins LC. Association between histological findings, aminotransferase levels and viral genotype in chronic hepatitis C infection. Rev Soc Bras Med Trop 2014;47:90-2. [PMID: 24553802 DOI: 10.1590/0037-8682-0008-2012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
232 Marinaki S, Boletis JN, Sakellariou S, Delladetsima IK. Hepatitis C in hemodialysis patients. World J Hepatol 2015; 7(3): 548-558 [PMID: 25848478 DOI: 10.4254/wjh.v7.i3.548] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 5.4] [Reference Citation Analysis]
233 García-Fulgueiras A, García-Pina R, Morant C, de Larrea-Baz NF, Alvarez E. Burden of disease related to hepatitis C and hepatitis B in Spain: a methodological challenge of an unfolding health problem. J Viral Hepat. 2011;18:e453-e460. [PMID: 21914063 DOI: 10.1111/j.1365-2893.2011.01467.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
234 Butt S, Idrees M, Shahid M, Amin I, Younas S, Afzal S, Akbar H, Ur Rehman I. Change in hepatitis C virus clades: a cross-sectional study of chronic HCV patients in Pakistan from 2000-2010. Eur J Clin Microbiol Infect Dis. 2011;30:669-672. [PMID: 21210169 DOI: 10.1007/s10096-010-1138-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
235 Papachristou E, Tsagkovits A, Zavitsanou A, Hatzakis A, Paraskevis D. HCV dispersal patterns among intravenous drug users (IDUs) in Athens metropolitan area. Infect Genet Evol 2016;45:415-9. [PMID: 27721034 DOI: 10.1016/j.meegid.2016.10.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
236 Park SH, Bang CS, Kim DJ. Biomarkers in HCV Infection. Adv Clin Chem 2015;70:131-96. [PMID: 26231487 DOI: 10.1016/bs.acc.2015.03.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
237 Herttua K, Mäkelä P, Martikainen P. Changes in alcohol-related mortality and its socioeconomic differences after a large reduction in alcohol prices: a natural experiment based on register data. Am J Epidemiol. 2008;168:1110-1118; discussion 1126-1131. [PMID: 18718894 DOI: 10.1093/aje/kwn216] [Cited by in Crossref: 122] [Cited by in F6Publishing: 114] [Article Influence: 8.7] [Reference Citation Analysis]
238 Wiegand J, Deterding K, Cornberg M, Wedemeyer H. Treatment of acute hepatitis C: the success of monotherapy with (pegylated) interferon alpha. J Antimicrob Chemother. 2008;62:860-865. [PMID: 18776191 DOI: 10.1093/jac/dkn346] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
239 Astell-Burt T, Flowerdew R, Boyle P, Dillon J. Is travel-time to a specialist centre a risk factor for non-referral, non-attendance and loss to follow-up among patients with hepatitis C (HCV) infection? Soc Sci Med 2012;75:240-7. [PMID: 22516762 DOI: 10.1016/j.socscimed.2012.02.046] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
240 Eltayeb AA, Abdou MAA, Abdel-aal AM, Othman MH. Vitamin D status and viral response to therapy in hepatitis C infected children. World J Gastroenterol 2015; 21(4): 1284-1291 [PMID: 25632203 DOI: 10.3748/wjg.v21.i4.1284] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
241 Bukh J. The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control. Journal of Hepatology 2016;65:S2-S21. [DOI: 10.1016/j.jhep.2016.07.035] [Cited by in Crossref: 117] [Cited by in F6Publishing: 111] [Article Influence: 19.5] [Reference Citation Analysis]
242 Sagnelli E, Starace M, Minichini C, Pisaturo M, Macera M, Sagnelli C, Coppola N. Resistance detection and re-treatment options in hepatitis C virus-related chronic liver diseases after DAA-treatment failure. Infection 2018;46:761-83. [DOI: 10.1007/s15010-018-1188-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
243 Grady B, van den Berg C, van der Helm J, Schinkel J, Coutinho R, Krol A, Prins M. No impact of hepatitis C virus infection on mortality among drug users during the first decade after seroconversion. Clin Gastroenterol Hepatol 2011;9:786-792.e1. [PMID: 21699803 DOI: 10.1016/j.cgh.2011.05.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
244 Lazarus JV, Bromberg DJ, Del Amo J, Norgaard O, García-Samaniego J, Casellas A, Calleja JL, Requena-Méndez A. Hepatitis C prevalence among the migrant population in Spain: A systematic review and meta-analysis. Enferm Infecc Microbiol Clin (Engl Ed) 2019;37:222-30. [PMID: 29759423 DOI: 10.1016/j.eimc.2018.04.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
245 Mitrovic N, Delic D, Markovic-Denic L, Jovicic M, Popovic N, Bojovic K, Simonovic Babic J, Svirtlih N. Seroprevalence and risk factors for hepatitis C virus infection among blood donors in Serbia: A multicentre study. Dig Liver Dis 2015;47:572-6. [PMID: 25882212 DOI: 10.1016/j.dld.2015.03.019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
246 Sillanpää M, Melén K, Porkka P, Fagerlund R, Nevalainen K, Lappalainen M, Julkunen I. Hepatitis C virus core, NS3, NS4B and NS5A are the major immunogenic proteins in humoral immunity in chronic HCV infection. Virol J 2009;6:84. [PMID: 19549310 DOI: 10.1186/1743-422X-6-84] [Cited by in Crossref: 27] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
247 Ueno Y, Sollano JD, Farrell GC. Prevention of hepatocellular carcinoma complicating chronic hepatitis C. J Gastroenterol Hepatol 2009;24:531-6. [PMID: 19368633 DOI: 10.1111/j.1440-1746.2009.05814.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
248 Jovanović M, Jovanović B, Potić M, Konstantinović L, Vrbić M, Radovanović-Dinić B, Kostić V. Characteristics of chronic hepatitis C among intravenous drug users: a comparative analysis. Bosn J Basic Med Sci 2010;10:153-7. [PMID: 20507297 DOI: 10.17305/bjbms.2010.2715] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
249 Walewska-Zielecka B, Religioni U, Juszczyk G, Wawrzyniak ZM, Czerw A, Soszyński P, Fronczak A. Anti-hepatitis C virus seroprevalence in the working age population in Poland, 2004 to 2014. Euro Surveill 2017;22:30441. [PMID: 28106526 DOI: 10.2807/1560-7917.ES.2017.22.2.30441] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
250 Lee KI, Park KS, Seo HJ, Kim TY, Kim ES, Jang BK, Chung WJ, Cho KB, Hwang JS. [Shifting in seroprevalence of HBsAg and anti-HCV during recent 10 years in adults resident in Daegu and Gyeongbuk province]. Korean J Gastroenterol 2011;58:82-7. [PMID: 21873822 DOI: 10.4166/kjg.2011.58.2.82] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
251 Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol. 2016;22:76-139. [PMID: 27044763 DOI: 10.3350/cmh.2016.22.1.76] [Cited by in Crossref: 42] [Cited by in F6Publishing: 52] [Article Influence: 7.0] [Reference Citation Analysis]
252 Mussini C, Antinori A, Bhagani S, Branco T, Brostrom M, Dedes N, Bereczky T, Girardi E, Gökengin D, Horban A, Lacombe K, Lundgren JD, Mendao L, Mocroft A, Oprea C, Porter K, Podlekareva D, Battegay M, d'Arminio Monforte A; European Aids Clinical Society. European AIDS Clinical Society Standard of Care meeting on HIV and related coinfections: The Rome Statements. HIV Med 2016;17:445-52. [PMID: 26492497 DOI: 10.1111/hiv.12347] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
253 Mena A, Moldes L, Meijide H, Cañizares A, Castro-Iglesias A, Delgado M, Pértega S, Pedreira J, Bou G, Poveda E. Seroprevalence of HCV and HIV infections by year of birth in Spain: impact of US CDC and USPSTF recommendations for HCV and HIV testing. PLoS One 2014;9:e113062. [PMID: 25436642 DOI: 10.1371/journal.pone.0113062] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
254 Saraswat V, Norris S, de Knegt RJ, Sanchez Avila JF, Sonderup M, Zuckerman E, Arkkila P, Stedman C, Acharya S, Aho I. Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 2. J Viral Hepat. 2015;22 Suppl 1:6-25. [PMID: 25560839 DOI: 10.1111/jvh.12350] [Cited by in Crossref: 81] [Cited by in F6Publishing: 70] [Article Influence: 11.6] [Reference Citation Analysis]
255 Berenguer J, Rivero A, Jarrín I, Núñez MJ, Vivancos MJ, Crespo M, Téllez MJ, Domingo P, Iribarren JA, Artero A, Márquez M, Santos I, Moreno J, Montero M, González-García J. Human Immunodeficiency Virus/Hepatitis C Virus Coinfection in Spain: Prevalence and Patient Characteristics. Open Forum Infect Dis 2016;3:ofw059. [PMID: 27186584 DOI: 10.1093/ofid/ofw059] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
256 Kieran J, Schmitz S, O'Leary A, Walsh C, Bergin C, Norris S, Barry M. The relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1. Clin Infect Dis 2013;56:228-35. [PMID: 23074309 DOI: 10.1093/cid/cis880] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
257 Gaudy-Graffin C, Lesage G, Kousignian I, Laperche S, Girault A, Dubois F, Goudeau A, Barin F. Use of an anti-hepatitis C virus (HCV) IgG avidity assay to identify recent HCV infection. J Clin Microbiol. 2010;48:3281-3287. [PMID: 20610669 DOI: 10.1128/jcm.00303-10] [Cited by in Crossref: 27] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
258 Kose S, Olmezoglu A, Gozaydin A, Ece G. Seroprevalence of hepatitis B and C among oncology patients in Turkey. J Health Popul Nutr 2011;29:652-5. [PMID: 22283040 DOI: 10.3329/jhpn.v29i6.9903] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
259 Choi S, Lee H, Lee H, Chung YS. A Healthcare-Associated Outbreak of HCV Genotype 2a at a Clinic in Seoul. Osong Public Health Res Perspect 2021;12:3-12. [PMID: 33659149 DOI: 10.24171/j.phrp.2021.12.1.02] [Reference Citation Analysis]
260 Kuo M, Janjua NZ, Burchell AN, Buxton JA, Krajden M, Gilbert M. Decreasing Hepatitis C Incidence Among a Population With Repeated Tests: British Columbia, Canada, 1993-2011. Am J Public Health 2015;105:1604-10. [PMID: 26066920 DOI: 10.2105/AJPH.2015.302591] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 1.9] [Reference Citation Analysis]
261 Di Lello FA, Neukam K, Parra-Sanchez M, Plaza Z, Soriano V, Cifuentes C, Mira JA, Poveda E, Pineda JA. Hepatitis C virus genotype 4 in Southern and Central Spain does not originate from recent foreign migration waves. J Med Virol. 2013;85:1734-1740. [PMID: 23861220 DOI: 10.1002/jmv.23657] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
262 González-Candelas F, Bracho MA, Wróbel B, Moya A. Molecular evolution in court: analysis of a large hepatitis C virus outbreak from an evolving source. BMC Biol. 2013;11:76. [PMID: 23870105 DOI: 10.1186/1741-7007-11-76] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 5.4] [Reference Citation Analysis]
263 Sacchini D, Craxì L, Refolo P, Minacori R, Cicchetti A, Gasbarrini A, Cammà C, Spagnolo AG; WEF Study Group. Ethical assessment of hepatitis C virus treatment: The lesson from first generation protease inhibitors. Dig Liver Dis 2015;47:351-5. [PMID: 25534233 DOI: 10.1016/j.dld.2014.11.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
264 Roncero C, Fuster D, Palma-álvarez RF, Rodriguez-cintas L, Martinez-luna N, Álvarez FJ. HIV And HCV infection among opiate-dependent patients and methadone doses: the PROTEUS study. AIDS Care 2017;29:1551-6. [DOI: 10.1080/09540121.2017.1313384] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
265 Fernández-Dávila P, Folch C, Ferrer L, Soriano R, Diez M, Casabona J. Hepatitis C virus infection and its relationship to certain sexual practices in men-who-have-sex-with-men in Spain: results from the European MSM internet survey (EMIS). Enferm Infecc Microbiol Clin 2015;33:303-10. [PMID: 25444047 DOI: 10.1016/j.eimc.2014.07.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
266 Stoll-Keller F, Barth H, Fafi-Kremer S, Zeisel MB, Baumert TF. Development of hepatitis C virus vaccines: challenges and progress. Expert Rev Vaccines. 2009;8:333-345. [PMID: 19249975 DOI: 10.1586/14760584.8.3.333] [Cited by in Crossref: 62] [Cited by in F6Publishing: 51] [Article Influence: 4.8] [Reference Citation Analysis]
267 Germer JJ, Mandrekar JN, Bendel JL, Mitchell PS, Yao JD. Hepatitis C virus genotypes in clinical specimens tested at a national reference testing laboratory in the United States. J Clin Microbiol. 2011;49:3040-3043. [PMID: 21613437 DOI: 10.1128/jcm.00457-11] [Cited by in Crossref: 24] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
268 Duffell EF, van de Laar MJ. Survey of surveillance systems and select prevention activities for hepatitis B and C, European Union/European Economic Area, 2009. Euro Surveill 2015;20:17-24. [PMID: 25860392 DOI: 10.2807/1560-7917.es2015.20.13.21080] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
269 McEwan P, Ward T, Bennett H, Kalsekar A, Webster S, Brenner M, Yuan Y. Estimating the clinical and economic benefit associated with incremental improvements in sustained virologic response in chronic hepatitis C. PLoS One 2015;10:e0117334. [PMID: 25635922 DOI: 10.1371/journal.pone.0117334] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
270 Saludes V, González-candelas F, Planas R, Solà R, Ausina V, Martró E. Evolutionary dynamics of the E1–E2 viral populations during combination therapy in non-responder patients chronically infected with hepatitis C virus subtype 1b. Infection, Genetics and Evolution 2013;13:1-10. [DOI: 10.1016/j.meegid.2012.09.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
271 Chueca N, Rivadulla I, Lovatti R, Reina G, Blanco A, Fernandez-Caballero JA, Cardeñoso L, Rodriguez-Granjer J, Fernandez-Alonso M, Aguilera A, Alvarez M, Galán JC, García F. Using NS5B Sequencing for Hepatitis C Virus Genotyping Reveals Discordances with Commercial Platforms. PLoS One 2016;11:e0153754. [PMID: 27097040 DOI: 10.1371/journal.pone.0153754] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
272 Bettaieb J, Chouikha A, Khedhiri M, Kharroubi G, Badreddine M, Bel Hadj Hmida N, Gharbi A, Hammemi W, Sadraoui A, Ben Yahia A, Meddeb Z, Ben Salah A, Triki H. Hepatitis C virus epidemiology in Central-West Tunisia: a population-based cross-sectional study. Arch Virol 2019;164:2243-53. [PMID: 31179516 DOI: 10.1007/s00705-019-04308-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
273 Werner CR, Franz C, Egetemeyr DP, Beck R, Malek NP, Lauer UM, Berg CP. First-generation protease inhibitor-triple therapy: SVR 24, safety, and predictors of response in a large single center cohort. Virol J. 2015;12:37. [PMID: 25889921 DOI: 10.1186/s12985-015-0261-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
274 Falla AM, Veldhuijzen IK, Ahmad AA, Levi M, Hendrik Richardus J. Limited access to hepatitis B/C treatment among vulnerable risk populations: an expert survey in six European countries. Eur J Public Health 2017;27:302-6. [PMID: 27542982 DOI: 10.1093/eurpub/ckw100] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
275 Lampertico P, Aghemo A, Viganò M, Colombo M. HBV and HCV therapy. Viruses 2009;1:484-509. [PMID: 21994557 DOI: 10.3390/v1030484] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
276 Derks L, Gassowski M, Nielsen S, An der Heiden M, Bannert N, Bock CT, Bremer V, Kücherer C, Ross S, Wenz B, Marcus U, Zimmermann R; DRUCK-study group. Risk behaviours and viral infections among drug injecting migrants from the former Soviet Union in Germany: Results from the DRUCK-study. Int J Drug Policy 2018;59:54-62. [PMID: 30005420 DOI: 10.1016/j.drugpo.2018.06.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
277 Turkova A, Volynets GV, Crichton S, Skvortsova TA, Panfilova VN, Rogozina NV, Khavkin AI, Tumanova EL, Indolfi G, Thorne C. Advanced liver disease in Russian children and adolescents with chronic hepatitis C. J Viral Hepat 2019;26:881-92. [PMID: 30803105 DOI: 10.1111/jvh.13093] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
278 Antaki N, Craxi A, Kamal S, Moucari R, Van der Merwe S, Haffar S, Gadano A, Zein N, Lai CL, Pawlotsky JM. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int. 2010;30:342-355. [PMID: 20015149 DOI: 10.1111/j.1478-3231.2009.02188.x] [Cited by in Crossref: 114] [Cited by in F6Publishing: 109] [Article Influence: 8.8] [Reference Citation Analysis]
279 Witthoeft T, Hueppe D, John C, Goelz J, Heyne R, Moeller B, Teuber G, Wollschlaeger S, Baumgarten A, Simon KG, Moog G, Dikopoulos N, Mauss S. Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in the daily routine treatment of patients with chronic hepatitis C in Germany: the PRACTICE study. J Viral Hepat 2010;17:459-68. [PMID: 20158603 DOI: 10.1111/j.1365-2893.2009.01255.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 11] [Article Influence: 0.3] [Reference Citation Analysis]
280 Crosignani A, Riva A, Della Bella S. Analysis of peripheral blood dendritic cells as a non-invasive tool in the follow-up of patients with chronic hepatitis C. World J Gastroenterol 2016; 22(4): 1393-1404 [PMID: 26819508 DOI: 10.3748/wjg.v22.i4.1393] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
281 Liberto MC, Marascio N, Zicca E, Matera G. Epidemiological features and specificities of HCV infection: a hospital-based cohort study in a university medical center of Calabria region. BMC Infect Dis. 2012;12 Suppl 2:S4. [PMID: 23173638 DOI: 10.1186/1471-2334-12-s2-s4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
282 Papić N, Budimir J, Kurelac I, Dušek D, Jugović D, Krajcar N, Vince A. Treatment of Elderly Patients with Chronic Hepatitis C: A Retrospective Cohort Study. Acta Clin Croat 2018;57:61-70. [PMID: 30256012 DOI: 10.20471/acc.2018.57.01.07] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
283 Andonov A, Kadkhoda K, Osiowy C, Kaita K. Pretreatment resistance to hepatitis C virus protease inhibitors boceprevir/telaprevir in hepatitis C virus subgenotype 1a-infected patients from Manitoba. Can J Gastroenterol 2013;27:414-6. [PMID: 23862174 DOI: 10.1155/2013/273856] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
284 European Association of the Study of the Liver. 2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines. Liver Int. 2012;32 Suppl 1:2-8. [PMID: 22212565 DOI: 10.1111/j.1478-3231.2011.02703.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 71] [Article Influence: 6.1] [Reference Citation Analysis]
285 Acero Fernández D, Ferri Iglesias MJ, Buxó Pujolràs M, López Nuñez C, Serra Matamala I, Queralt Molés X, Aldeguer Manté X. Changes in the epidemiology and distribution of the hepatitis C virus genotypes in North-Eastern Spain over the last 35 years. Gastroenterol Hepatol 2018;41:2-11. [PMID: 29150360 DOI: 10.1016/j.gastrohep.2017.09.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
286 Li Y, Ramirez S, Humes D, Jensen SB, Gottwein JM, Bukh J. Differential Sensitivity of 5′UTR-NS5A Recombinants of Hepatitis C Virus Genotypes 1−6 to Protease and NS5A Inhibitors. Gastroenterology 2014;146:812-821.e4. [DOI: 10.1053/j.gastro.2013.11.009] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 5.6] [Reference Citation Analysis]
287 Chen YY, Chen CL, Chen JW, Hsu NT, Wei ST, Hou SM, Lu SN, Chen PJ. Secular Trends and Geographic Maps of Hepatitis C Virus Infection among 4 Million Blood Donors in Taiwan from 1999 to 2017. Hepatol Commun 2020;4:1193-205. [PMID: 32766478 DOI: 10.1002/hep4.1531] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
288 Yi S, Mun P, Chhoun P, Chann N, Tuot S, Mburu G. Prevalence of and risk factors for hepatitis C virus antibody among people who inject drugs in Cambodia: a national biological and behavioral survey. Harm Reduct J 2019;16:29. [PMID: 31036011 DOI: 10.1186/s12954-019-0299-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
289 Urbanus AT, van de Laar TJ, van den Hoek A, Zuure FR, Speksnijder AG, Baaten GG, Heijman T, Vriend HJ, Op de Coul EL, Coutinho RA. Hepatitis C in the general population of various ethnic origins living in the Netherlands: should non-Western migrants be screened? J Hepatol. 2011;55:1207-1214. [PMID: 21703202 DOI: 10.1016/j.jhep.2011.02.028] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
290 Li PY, Zhou XJ, Yao L, Fang XH, Ren JN, Song JW. Novel biosensor-based microarray assay for detecting rs8099917 and rs12979860 genotypes. World J Gastroenterol 2012; 18(44): 6481-6488 [PMID: 23197895 DOI: 10.3748/wjg.v18.i44.6481] [Cited by in CrossRef: 1] [Article Influence: 0.1] [Reference Citation Analysis]
291 Degasperi E, Caprioli F, El Sherif O, Back D, Colombo M, Aghemo A. Challenges in treating patients with inflammatory bowel disease and concurrent viral hepatitis infection. Expert Rev Gastroenterol Hepatol. 2016;10:1373-1383. [PMID: 27718758 DOI: 10.1080/17474124.2016.1246181] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
292 Butt S, Idrees M, Akbar H, ur Rehman I, Awan Z, Afzal S, Hussain A, Shahid M, Manzoor S, Rafique S. The changing epidemiology pattern and frequency distribution of hepatitis C virus in Pakistan. Infect Genet Evol. 2010;10:595-600. [PMID: 20438863 DOI: 10.1016/j.meegid.2010.04.012] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
293 Bensalem A, Selmani K, Hihi N, Bencherifa N, Mostefaoui F, Kerioui C, Pineau P, Debzi N, Berkane S. Eastern region represents a worrying cluster of active hepatitis C in Algeria in 2012. J Med Virol 2016;88:1394-403. [PMID: 26856380 DOI: 10.1002/jmv.24491] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
294 Sagnelli E, Santantonio T, Coppola N, Fasano M, Pisaturo M, Sagnelli C. Acute hepatitis C: clinical and laboratory diagnosis, course of the disease, treatment. Infection 2014;42:601-10. [DOI: 10.1007/s15010-014-0608-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]